[
    "Клинические рекомендации «Синдром раздраженного кишечника». Год утверждения 2021. Электронный ресурс: https://cr.minzdrav.gov.ru/recomend/190_2, дата доступа: 06.12.2023",
    "Клинические рекомендации «Язвенный колит». Год утверждения 2020. Электронный ресурс: https://cr.minzdrav.gov.ru/recomend/193_1, дата доступа: 06.12.2023",
    "Клинические рекомендации «Болезнь крона». Год утверждения 2020. Электронный ресурс: https://cr.minzdrav.gov.ru/recomend/176_1, дата доступа: 06.12.2023",
    "Клинические рекомендации «Дивертикулярная болезнь». Год утверждения 2023. Электронный ресурс: https://cr.minzdrav.gov.ru/recomend/179_2, дата доступа: 06.12.2023",
    "British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Vasant DH, Paine PA, Black CJ, et al. Gut 2021;70:1214–1240.",
    "Irritable bowel syndrome in adults: diagnosis and management. NICE clinical guideline. Published: 23 February 2008. Last updated: 4 April 2017. Электронный ресурс: www.nice.org.uk/guidance/cg61, дата доступа: 06.12.2023",
    "Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022;10(6):556–84. https://doi.org/10.1002/ueg2.12259",
    "Diverticular disease: diagnosis and management. NICE clinical guideline. Published: 27 November 2019. Электронный ресурс: https://www.nice.org.uk/guidance/ng147, дата доступа: 06.12.2023",
    "Официальный сайт Rome Foundation. Критерии Рим IV. Электронный ресурс: https://theromefoundation.org/rome-iv/rome-iv-criteria/, дата доступа: 06.12.2023",
    "Ивашкин В.Т., Ляшенко О.С., Драпкина О.М., Алексеева О.П., Алексеенко С.А., Андреев Д.Н., Барановский А.Ю., Голощапов О.В., Железнова Н.В., Зольникова О.Ю., Кляритская И.Л., Корочанская Н.В., Лапина Т.Л., Маев И.В., Масленников Р.В., Мязин Р.Г., Павлов П.В., Перекалина М.В., Писаренко Н.А., Повторейко А.В., Полуэктова Е.А., Секретарева Л.А., Ткачев А.В., Трошкина Ю.М., Трухманов А.С., Ульянин А.И., Филатова С.Г., Цуканов В.В., Шифрин О.С. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ), Российской гастроэнтерологической ассоциации РГА и Российского общества по профилактике неинфекционных заболеваний по диагностике и лечению Clostridioides difficile (C. difficile)-ассоциированной болезни у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(3):85–119. https://doi.org/10.22416/1382-4376- 2023-33-3-85-119",
    "Клинические рекомендации «Синдром избыточного бактериального роста». Год утверждения 2023. Электронный ресурс: https://www.gastro.ru/userfiles/R_SIBR-23.pdf, дата доступа: 06.12.2023",
    "Okawa Y. A Discussion of Whether Various Lifestyle Changes can Alleviate the Symptoms of Irritable Bowel Syndrome. Healthcare (Basel). 2022 Oct 12;10(10):2011. doi:10.3390/healthcare10102011. PMID: 36292457; PMCID: PMC9602372.",
    "Синдром раздраженного кишечника: диета, образ жизни и лекарственные препараты. Сайт национальной системы здравоохранения Великобритании. Электронный ресурс: https://www.nhs.uk/conditions/irritable-bowel-syndrome-ibs/diet-lifestyle-and-medicines/, дата доступа: 06.12.2023",
    "Tursi A, Papa V, Lopetuso LR, Vetrone LM, Gasbarrini A, Papa A. When to Perform a Colonoscopy in Diverticular Disease and Why: A Personalized Approach. J Pers Med. 2022 Oct 14;12(10):1713. doi: 10.3390/jpm12101713. PMID: 36294852; PMCID: PMC9605603.",
    "Fejleh MP, Tabibian JH. Colonoscopic management of diverticular disease. World J Gastrointest Endosc. 2020 Feb 16;12(2):53-59. doi: 10.4253/wjge.v12.i2.53. PMID: 32064030; PMCID: PMC6965002.",
    "Nielsen OH, Fernandez-Banares F, Sato T, Pardi DS. Microscopic colitis: Etiopathology, diagnosis, and rational management. Elife. 2022 Aug 1;11:e79397. doi: 10.7554/eLife.79397. PMID: 35913459; PMCID: PMC9342949.",
    "Андреев Д.Н., Маев И.В., Кучерявый Ю.А., Черёмушкин С.В. Микроскопический колит с позиций современной гастроэнтерологии. Consilium Medicum. 2021; 23 (5): 395–401. DOI: 10.26442/20751753.2021.5.200888",
    " Микроскопический колит: клинические формы, диагностика, лечение/ Ивашкин В.Т., Шептулин А.А., Шифрин О.С., Галимова С.Ф., Юрманова Е.Н.//РЖГГК. – 2006. – №6.",
    "Микроскопический колит: современное состояние проблемы/ Тертычный А.С., Ахриева Х.М., Зайратьянц О.В., Селиванова Л.С., Шароян Ж.В., Епифанова Е.И., Таширова Е.А., Маренич Н.С.// Гастроэнтерология. – 2015. – №3.",
    "Микроскопические колиты: критерии диагноза, течение, прогноз, лечебная тактика/ Григоренко Е.И.// Крымский терапевтический журнал. – 2008 – №2.",
    "Микроскопический колит с позиций современной гастроэнтерологии/ Андреев Д.Н., Маев И.В., Кучерявый Ю.А., Черёмушкин С.В.// CONSILIUM MEDICUM. ‒ 2021; 23.",
    "Rubio-Tapia, Alberto MD1; Hill, Ivor D. MD2; Semrad, Carol MD3; Kelly, Ciarán P. MD4; Greer, Katarina B. MD, MS5; Limketkai, Berkeley N. MD, PhD, FACG6; Lebwohl, Benjamin MD, MS7. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. The American Journal of Gastroenterology 118(1):p 59-76, January 2023. | DOI: 10.14309/ajg.0000000000002075",
    "Министерство здравоохранения РФ. Клинические рекомендации «Шигеллез у взрослых». Год утверждения: 2016. Электронный ресурс: https://antimicrob.net/wp-content/uploads/SHinellez-u-vzroslykh.pdf, дата доступа: 06.12.2023",
    "Министерство здравоохранения РФ. Клинические рекомендации «Сальмонеллез у взрослых». Год утверждения: 2021. Электронный ресурс: https://legalacts.ru/doc/klinicheskie-rekomendatsii-salmonellez-u-vzroslykh-utv-minzdravom-rossii/, дата доступа: 06.12.2023",
    "Клинические рекомендации «Рак прямой кишки». Год утверждения 2022. Электронный ресурс: https://cr.minzdrav.gov.ru/recomend/554_3, дата доступа: 06.12.2023",
    "Клинические рекомендации «Хронический панкреатит». Год утверждения 2020. Электронный ресурс: https://cr.minzdrav.gov.ru/recomend/273_4, дата доступа: 06.12.2023",
    "Kou Nagasaco Дифференциальная диагностика заболеваний прямой и ободочной кишки (электронный вариант) Электронный ресурс: https://www.colonoscopy.ru/projects/nagasako/texts/1-1.html, дата доступа: 06.12.2023",
    "Mathews AA, Draganov PV, Yang D. Endoscopic management of colorectal polyps: From benign to malignant polyps. World J Gastrointest Endosc. 2021 Sep 16;13(9):356-370. doi: 10.4253/wjge.v13.i9.356. PMID: 34630886; PMCID: PMC8474698.",
    "Rutter MD, Chattree A, Barbour JA, et al. Gut Published Online First: [please include Day Month Year] doi:10.1136/ gutjnl-2015-309576",
    "Tanaka, S., Saitoh, Y., Matsuda, T. et al. Evidence-based clinical practice guidelines for management of colorectal polyps. J Gastroenterol 56, 323–335 (2021). https://doi.org/10.1007/s00535-021-01776-1",
    "Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. DOI: https://dx.doi.org/10.1055/s-0043-102569 | Endoscopy 2017; 49(03): 270-297",
    "Лазебник Л. Б., Сарсенбаева А. С., Авалуева Е. Б., Орешко Л. С., Ситкин С. И., Голованова Е. В., Туркина С. В., Хлынова О. В., Сагалова О. И., Мирончев О. В. Клинические рекомендации «Хронические диареи у взрослых». Экспериментальная и клиническая гастроэнтерология. 2021;188(4): 7–67. DOI: 10.31146/1682-8658-ecg-188-4-7-67",
    "Lawrence R. Schiller, Darrell S. Pardi, Joseph H. Sellin. Chronic Diarrhea: Diagnosis and Management. Clinical Gastroenterology and Hepatology 2017;15:182–193",
    "Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd editionArasaradnam RP, Brown S, Forbes A, et al. Gut doi:10.1136/gutjnl-2017-315909",
    "Reznikov, E.A.; Suskind, D.L. Current Nutritional Therapies in Inflammatory Bowel Disease: Improving Clinical Remission Rates and Sustainability of Long-Term Dietary Therapies. Nutrients 2023, 15, 668. https://doi.org/10.3390/nu15030668",
    "Руководство по лабораторным методам диагностики. А.А. Кишкун. ГЭОТАР-Медиа, 2014 г.  ISBN: 978-5-9704-2659-3 , 978-5-9704-3102-3",
    "Вельков В. В. С-белок – структура, функция, методы определения / В. В. Вельков // Медицинский дайджест. Медэксперт. – 2008. – № 2. – С 33-36.",
    "Chernecky C. C. Laboratory tests and diagnostic procedures / C. C. Chernecky, B. J. Berger; 5th ed. – Saunder Elsevier, 2008. – 1232 pp.",
    "Кишкун А. А. Иммунологические и серологические исследования в клинической практике / А. А. Кишкун. – ООО Медицинское информационное агентство, 2006. – 536 с.",
    "Wilson D.D. McGraw-Hill Manual of Laboratory and Diagnostic Tests / D D. Wilson. – McGraw-Hill Medical, 2007. – 608 pp",
    "Цирроз и фиброз печени : клинические рекомендации / Российское общество по изучению печени, Российская гастроэнтерологическая ассоциация. 2021.",
    "Рак печени (гепатоцеллюлярный) : клинические рекомендации / Ассоциация онкологов России, Российское общество клинической онкологии, Российское общество рентгенологов и радиологов. 2020.",
    "Liver Function Tests / MedlinePlus: National Library of Medicine. 2022.",
    "Lala V., Zubair M., Minter D. A. Liver Function Tests / StatPearls. 2022.",
    "Ивашкин В. Т., Маевская М. В., Павлов Ч. С. и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2017. В. 27(6). С. 20–40.",
    "Шифф Ю. Р., Соррел М. Ф., Мэддрей У. С. Введение в гепатологию / под ред. В. Т. Ивашкина, А. О. Буеверова, М. В. Маевской. М., 2011.",
    "Colombo M. EASL clinical practice guidelines for the management of occupational liver diseases // Liver Int., 2020. Vol. 40(1). P. 136–141. doi:10.1111/liv.14349",
    "Newsome P., Cramb R., Davison S., et al. Guidelines on the management of abnormal liver blood tests // Gut, 2018. Vol. 67. P. 6–19. doi:10.1136/gutjnl-2017-314924",
    "Herfarth HH, Martin CF, Sandler RS, Kappelman MD, Long MD. Prevalence of a gluten-free diet and improvement of clinical symptoms in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Jul;20(7):1194-7. doi: 10.1097/MIB.0000000000000077. PMID: 24865778; PMCID: PMC4331053.",
    "Saadati S, Sadeghi A, Mohaghegh-Shalmani H, Rostami-Nejad M, Elli L, Asadzadeh-Aghdaei H, Rodrigo L, Zali MR. Effects of a gluten challenge in patients with irritable bowel syndrome: a randomized single-blind controlled clinical trial. Sci Rep. 2022 Mar 23;12(1):4960. doi: 10.1038/s41598-022-09055-6. PMID: 35322144; PMCID: PMC8943127.",
    "Rej A, Sanders DS. Gluten-Free Diet and Its 'Cousins' in Irritable Bowel Syndrome. Nutrients. 2018 Nov 11;10(11):1727. doi: 10.3390/nu10111727. PMID: 30423854; PMCID: PMC6266983.",
    "Hajiani E, Masjedizadeh A, Shayesteh AA, Babazadeh S, Seyedian SS. Comparison between gluten-free regime and regime with gluten in symptoms of patients with irritable bowel syndrome (IBS). J Family Med Prim Care. 2019 May;8(5):1691-1695. doi: 10.4103/jfmpc.jfmpc_464_18. PMID: 31198738; PMCID: PMC6559066.",
    "Маев И.В., Охлобыстина О.З., Халиф И.Л., Андреев Д.Н. Синдром раздраженного кишечника в Российской Федерации – результаты многоцентрового наблюдательного исследования ROMERUS. Терапевтический архив. 2023;95(1):1–14.",
    "Минушкин О.Н., Елизаветина Г.А. Форлакс в лечении хронических запоров: особенности терапии пожилых больных. РМЖ. 2006;1:31. Электронный ресурс: https://www.rmj.ru/articles/bolezni_organov_pishchevareniya/Forlaks_v_lechenii_hronicheskih_zaporov_osobennosti_terapii_poghilyh_bolynyh/#ixzz8L99pX0Y3, дата доступа: 06.12.2023",
    "Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927.",
    "Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38:1569.",
    "Jones R, Lydeard S. Irritable bowel syndrome in the general population. BMJ 1992; 304:87.",
    "Heaton KW, O'Donnell LJ, Braddon FE, et al. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 1992; 102:1962.",
    "Ford AC, Forman D, Bailey AG, et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008; 103:1229.",
    "Sayuk GS, Wolf R, Chang L. Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol 2017; 112:892.",
    "Schuster MM. Diagnostic evaluation of the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20:269.",
    "Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122:1500.",
    "Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100:998.",
    "American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1:S1.",
    "Hahn BA, Saunders WB, Maier WC. Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms. Dig Dis Sci 1997; 42:2585.",
    "Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95:2816.",
    "Thompson WG, Irvine EJ, Pare P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47:225.",
    "Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10:712.",
    "Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003; 17:643.",
    "Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107:991.",
    "Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480.",
    "Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. Am J Gastroenterol 2012; 107:1793.",
    "Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986; 27:37.",
    "Hershfield NB. Nongastrointestinal symptoms of irritable bowel syndrome: an officebased clinical survey. Can J Gastroenterol 2005; 19:231.",
    "Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313:949.",
    "Swarbrick ET, Hegarty JE, Bat L, et al. Site of pain from the irritable bowel. Lancet 1980; 2:443.",
    "Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep 2017; 19:15.",
    "Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2:653.",
    "Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016.",
    "Smalley W, Falck-Ytter C, Carrasco-Labra A, et al. AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology 2019; 157:851.",
    "Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2016; 44:693.",
    "Talley NJ, Phillips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut 1990; 31:77.",
    "Smith RC, Greenbaum DS, Vancouver JB, et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991; 100:591.",
    "Taub E, Cuevas JL, Cook EW 3rd, et al. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dig Dis Sci 1995; 40:2647.",
    "Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87:1.",
    "Frigerio G, Beretta A, Orsenigo G, et al. Irritable bowel syndrome. Still far from a positive diagnosis. Dig Dis Sci 1992; 37:164.",
    "Hammer J, Talley NJ. Diagnostic criteria for the irritable bowel syndrome. Am J Med 1999; 107:5S.",
    "Fass R, Longstreth GF, Pimentel M, et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001; 161:2081.",
    "Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94:2912.",
    "Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145:1262.",
    "Talley NJ. How to do and interpret a rectal examination in gastroenterology. Am J Gastroenterol 2008; 103:820.",
    "Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021; 116:17.",
    "Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110:444.",
    "Ford AC, Chey WD, Talley NJ, et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009; 169:651.",
    "Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011; 141:1187.",
    "Rezaie A, Park SC, Morales W, et al. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci 2017; 62:1480.",
    "Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 2015; 10:e0126438.",
    "Schmulson M, Balbuena R, Corona de Law C. Clinical experience with the use of anti- CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico. Rev Gastroenterol Mex 2016; 81:236.",
    "Schmulson MW, Chang L. Diagnostic approach to the patient with irritable bowel syndrome. Am J Med 1999; 107:20S.",
    "Svendsen JH, Munck LK, Andersen JR. Irritable bowel syndrome prognosis and diagnostic safety. A 5-year follow-up study. Scand J Gastroenterol 1985; 20:415.",
    "O'Connor OJ, McSweeney SE, McWilliams S, et al. Role of radiologic imaging in irritable bowel syndrome: evidence-based review. Radiology 2012; 262:485.",
    "Guagnozzi D, Arias Á, Lucendo AJ. Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. Aliment Pharmacol Ther 2016; 43:851.",
    "Kamp EJ, Kane JS, Ford AC. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14:659.",
    "Gudsoorkar VS, Quigley EM. Distinguishing Microscopic Colitis From Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2016; 14:669.",
    "Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol 2012; 55:36.",
    "El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19:861.",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Krazati (adagrasib) [prescribing information]. San Diego, CA: Mirati Therapeutics, Inc; December 2022.",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J. Contributions of CYP2D6, CYP2C9, and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002;12(7):571-580. [PubMed 12360109].",
    "Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31(6):347-353. [PubMed 8685072].",
    "Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-350. [PubMed 16584282].",
    "Gilurytmal [summary of product characteristics] Bahnhofstrasse, Germany: Carinopharm GmbH; September 2013.",
    "Broly F, Libersa C, Lhermitte M, Dupuis B. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol. 1990;39(6):1045-1053. [PubMed 2322292].",
    "Dymista (azelastine/fluticasone) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; September 2018.",
    "Astelin (azelastine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; September 2018.",
    "Astepro (azelastine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; September 2018.",
    "Verre M, Bossio F, Mammone A, et al. Serotonin syndrome caused by olanzapine and clomipramine. Minerva Anestesiol. 2008;74(1-2):41-45. [PubMed 18004234].",
    "Kohen I, Gordon ML, Manu P. Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants: two case reports. CNS Spectr. 2007;12(8):596-598. [PubMed 17667887].",
    "Kaufman KR, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry. 2006;18(3):201-204. [PubMed 16923659].",
    "Marlowe K, Schirgel D. Quetiapine and citalopram: aetiological significances in serotonin syndrome. N Z Med J. 2006;119(1237):U2058. [PubMed 16862204].",
    "Chopra P, Ng C, Schweitzer I. Serotonin syndrome associated with fluoxetine and olanzapine. World J Biol Psychiatry. 2004;5(2):114-115. [PubMed 15179671].",
    "Karki SD, Masood GR. Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother. 2003;37(3):388-391. [PubMed 12639169].",
    "Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother. 2002;36(1):67-71. [PubMed 11816261].",
    "Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG, Christodoulou GN. Olanzapine-associated neuroleptic malignant syndrome: is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry. 2003;2(1):10. [PubMed 14613516].",
    "Kim JM, Lee ST, Song EC, et al. Neurotoxic syndrome developed after taking sertraline and risperidone. J Clin Neurol. 2007;3(3):165-167. [PubMed 19513287].",
    "Gambassi G, Capurso S, Tarsitani P, Liperoti R, Bernabei R. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res. 2006;18(3):266-270. [PubMed 16804375].",
    "Matsumoto R, Kitabayashi Y, Nakatomi Y, Tsuchida H, Fukui K. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry. 2005;162(4):812. [PubMed 15800166].",
    "Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry. 2005;162(2):397-398. [PubMed 15677611].",
    "Kontaxakis VP, Havaki-Kontaxaki BJ, Pappa DA, Katritsis DE, Christodoulou GN. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine. J Clin Psychopharmacol. 2003;23(6):671-672. [PubMed 14624202].",
    "Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446].",
    "Tudorza Pressair (aclidinium) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2019.",
    "Duaklir Pressair (aclidinium bromide and formoterol fumarate) [prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc.; March 2019.",
    "Aricept (donepezil) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2013.",
    "Razadyne (galantamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; June 2013.",
    "Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.",
    "Bloxiverz (neostigmine methylsulfate) [prescribing information]. Chesterfield, MO: Eclat Pharmaceuticals; May 2013.",
    "Mestinon (pyridostigmine) [prescribing information]. Costa Mesa, CA: ICN Pharmaceuticals Inc; July 2001.",
    "Enlon (edrophonium) [prescribing information]. Lake Forest, IL: Bioniche Pharma USA LLC; March 2010.",
    "Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.",
    "Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011.",
    "Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=20010056Accessed May 1, 2015.",
    "Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015.",
    "Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.",
    "Superan (alizapride) [summary of product characteristics]. Sao Paulo, Brazil: Sanofi-Aventis Pharmaceuticals Ltda; August 2016.",
    "Worthley LI. Clinical toxicology: Part I. Diagnosis and management of common drug overdosage. Crit Care Resusc. 2002;4(3):192-215. [PubMed 16573429].",
    "Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia. 2007;27(12):1421-1423. [PubMed 17868285].",
    "Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996;16(5):323-327. [PubMed 8869767].",
    "Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother. 1998;32(1):33-38. [PubMed 9475817].",
    "Soldin OP, Tonning JM. Serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008;358(20):2185-2186. [PubMed 18480219].",
    "Wooltorton E. Triptan migraine treatments and antidepressants: risk of serotonin syndrome. CMAJ. 2006;175(8):874. [PubMed 16988028].",
    "Imitrex (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2018.",
    "Maxalt (rizatriptan) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2011.",
    "Axert (almotriptan) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2017.",
    "Relpax (eletriptan) [prescribing information]. New York, NY: Pfizer Inc; September 2013.",
    "Frova (frovatriptan) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; August 2018.",
    "Amerge (naratriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.",
    "Zomig (zolmitriptan) [prescribing information]. Hayward, CA: Impax Specialty Pharma; December 2018.",
    "Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and Triptans: an analysis of the 29 case reports. MedGenMed. 2007;9(3):48. [PubMed 18092054].",
    "Evans RW. Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome? Headache. 2008;48(4):639-640. [PubMed 18377388].",
    "Orlova Y, Rizzoli P, Loder E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol. 2018;75(5):566-572. [PubMed 29482205].",
    "Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089-1099. [PubMed 20618823].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Altman CS, Jahangiri MF. Serotonin syndrome in the perioperative period. Anesth Analg. 2010;110(2):526-528. [PubMed 19955502].",
    "Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999;13(3):313-317. [PubMed 10512094].",
    "Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol. 2010;24(10):1433-1438. [PubMed 19423610].",
    "Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. J Clin Anesth. 2012;24(3):251-252. [PubMed 22537574].",
    "Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics. 2001;42(3):258-260. [PubMed 11351116].",
    "Sorscher SM. Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist. J Psychopharmacol. 2002;16(2):191. [PubMed 12095081].",
    "George M, Al-Duaij N, O’Donnell KA, Shannon MW. Obtundation and seizure following ondansetron overdose in an infant. Clin Toxicol (Phila). 2008;46(10):1064-1066. [PubMed 18803119].",
    "Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondansetron is associated with lethal outcome. Pediatrics. 2010;125(6):e1514-e1517. [PubMed 20439600].",
    "Zofran (ondansetron) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2017.",
    "Anzemet (dolasetron) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; September 2014.11. Sancuso (granisetron) transdermal system [prescribing information]. Bedminster, NJ: Kyowa Kirin Inc; January 2017.",
    "Aloxi (palonosetron) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2014.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Uroxatral (alfuzosin) [prescribing information]. Cary, NC: Covis Pharmaceuticals Inc; April 2014.",
    "Bruckner HW, Schleifer SJ. Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction. Cancer Treat Rep. 1983;67(5):516. [PubMed 6406063].",
    "Hexalen (altretamine) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; May 2009.",
    "Symmetrel (amantadine) tablets [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals Inc; January 2009.",
    "Gocovri (amantadine) extended-release capsules [prescribing information]. Emeryville, CA: Adamas Pharma LLC; August 2017.",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.",
    "Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84-90. [PubMed 9262938].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Gillman PK. Serotonin syndrome--clomipramine too soon after moclobemide? Int Clin Psychopharmacol. 1997;12(6):339-342. [PubMed 9547136].",
    "Graham PM, Potter JM, Patterson J. Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction. Lancet. 1982;2(8295):440. [PubMed 6124828].",
    "Dardennes RM, Even C, Ballon N, Bange F. Serotonin syndrome caused by a clomipramine-moclobemide interaction. J Clin Psychiatry. 1998;59(7):382-383. [PubMed 9714270].",
    "Geighner JP, Boyer WF, Tyler DL, Neborsky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry. 1990;51(6):222-225. [PubMed 2347858].",
    "Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med. 1994;24(5):983-985. [PubMed 7978579].",
    "Benazzi F. Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry. 1996;29(4):162. [PubMed 8858717].",
    "Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm. 1993;12(3):222-225. [PubMed 8491079].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Marplan (isocarboxazid) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2018.",
    "Nardil (phenelzine) [prescribing information]. New York, NY: Parke-Davis; May 2007.",
    "Parnate (tranylcypromine) [prescribing information]. St. Michael, Barbados; Concordia Pharmaceuticals Inc.; January 2018.",
    "Clomipramine [prescribing information]. Pennington, NJ: Zydus Pharmaceuticals (USA) Inc.; May 2019.",
    "Desipramine [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; January 2019.",
    "Nortriptyline [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; June 2019.",
    "Trimipramine [prescribing information]. Boca Raton, FL: Breckenridge Pharmaceutical, Inc.; July 2017.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Firdapse (amifampridine) [prescribing information]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.; November 2018.",
    "Firdapse (amifampridine) [summary of product characteristics]. London, United Kingdom: BioMarin Europe Limited; June 2017.",
    "Ethyol (amifostine) [prescribing information]. Bedford, OH: BenVenue Inc; November 2008.",
    "Apokyn (apomorphine) [prescribing information]. Louisville, KY: US WorldMeds LLC; July 2014.",
    "Velcade (bortezomib) [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc; September 2015.",
    "Cycloset (bromocriptine) [prescribing information]. Tiverton, RI: VeroScience LLC; October 2015.",
    "Marplan (isocarboxazid) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals; June 2007.",
    "Sinemet (carbidopa levodopa) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; July 2014.",
    "Nardil (phenelzine) [prescribing information]. New York, NY: Pfizer Inc; May 2007.",
    "Adempas (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2014.",
    "Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013.",
    "Parnate (tranylcypromine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2008.",
    "Briant RH, Reid JL, and Dollery CT. Interaction between clonidine and desipramine in man. Br Med J. 1973;1(5852):522-3. [PubMed 4571186].",
    "Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. J Am Ger Soc. 1983;31(3):164-5. [PubMed 6827017].",
    "Buckley M and Feely J. Antagonism of antihypertensive effect of guanfacine by tricyclic antidepressants. Lancet. 1991;337(8750):1173-4. [PubMed 1674059].",
    "Stiff JL and Harris DB. Clonidine withdrawal complicated by amitriptyline therapy. Anesthesiology. 1983;59(1):73-4. [PubMed 6859615].",
    "Prescribing information. Alphagan (brimonidine). Irvine, CA: Allergan, Inc., 12/2001.",
    "Prescribing information. Alphagan-P (brimonidine). Irvine, CA: Allergan, Inc., 5/2010.",
    "Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011;162(6):959-965. [PubMed 22137067].",
    "Ast J, Jablecka A, Bogdanski P, Smolarek I, Krauss H, Chmara E. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Med Sci Monit. 2010;16(5):CR266-271. [PubMed 20424555].",
    "Palloshi A, Fragasso G, Piattie P, et al. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am J Cardiol. 2004;93(7):933-935. [PubMed 15050504].",
    "Huynh NT, Tayek JA. Oral arginine reduces systemic blood pressure in type 2 diabetes: its potential role in nitric oxide generation. J Am Coll Nutr. 2002;21(5):422-427. [PubMed 12356784].",
    "Cheng JW, Baldwin SN. L-arginine in the management of cardiovascular diseases. Ann Pharmacotherapy.2001;35(6):755-764. [PubMed 11408995].",
    "Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 2001;163(4):887-891. [PubMed 11282761].",
    "Komers R, Komersova K, Kazdova L, Ruzickova J, Pelikanova T. Effect of ACE inhibition and angiotensin AT1 receptor blockade on renal and blood pressure response to L-arginine in humans. J Hypertens. 2000;18(1):51-59. [PubMed 10678543].",
    "Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H, Kajiyama G. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension. 1995;25(4 pt 2):989-902. [PubMed 7721451].",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Aristada (aripiprazole lauroxil) [prescribing information]. Waltham, MA: Alkermes, Inc.; February 2020.",
    "Coartem (artemether/lumefantrine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2019.",
    "Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163(1):59-64. [PubMed 12523917].",
    "de Abajo FJ, Rodriguez LA, Montero D. Associated between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106-1109. [PubMed 10531103].",
    "van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323(7314):655-658. [PubMed 11566827].",
    "Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, Egberts ACG. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164(21):2367-2370. [PubMed 15557417].",
    "Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513. [PubMed 18332297].",
    "de Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-1109. [PubMed 10531103].",
    "Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther. 2005;22:175-181. [PubMed 16091054].",
    "Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. BMJ. 351:h3517. [PubMed 26173947].",
    "Hou PC, Lin FJ, Lin SY, Hwang TJ, Wang CC. Risk of intracranial hemorrhage with concomitant use of antidepressants and nonsteroidal anti-inflammatory drugs: a nested case-control study. Ann Pharmacother. 2021;55(8):941-948. [PubMed 33305585].",
    "Jeong HE, Oh I-S, Kim WJ, Shin J-Y. Risk of major adverse cardiovascular events associated with concomitant use of antidepressants and non-steroidal anti-inflammatory drugs: a retrospective cohort study. CNS Drugs. 2020;34(10:1063-1074. [PubMed 32737794].",
    "Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006;26(9):1307-1313. [PubMed 16945053].",
    "Weinrieb RM, Auriacombe M, Lynch KG, et al. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf. 2005;4:337-344. [PubMed 15794724].",
    "Silverglat MJ. Baclofen and tricyclic antidepressants: possible interaction. JAMA. 1981;246(15):1659. [PubMed 7277640].",
    "Beermann B, Groschinsky-Grind M. Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline. Eur J Clin Pharmacol. 1978;13(5):385-387. [PubMed 668798].",
    "Eid TJ, Horton M, Hendrix C, Yu JM, Browning EA, Malhotra A. A First Report of HCTZ and Dicyclomine Induced Uncharacteristic Contraction Alkalosis. J Pharm Pract. 2023;36(3):679-684. [PubMed 34670427].",
    "Inhibace Plus (cilazapril and hydrochlorothiazide) [product monograph]. Mississauga, ON: Xediton Pharmaceuticals Inc; August 2022.",
    "Hylaton (chlortalidone) [summary of product characteristics]. Leicester, UK: Morningside Healthcare Limited; February 2020.",
    "Diovan HCT (valsartan and hydrochlorothiazide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2020.",
    "Thalitone (chlorthalidone) [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; September 2019.",
    "Microzide (hydrochlorothiazide) [prescribing information]. Madison, NJ: Allergan USA, Inc.; August 2020.",
    "Hyzaar (losartan potassium and hydrochlorothiazide) [prescribing information]. Jersey City, NJ: Organon &amp; Co.; March 2023.",
    "Lonasen (blonanserin) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200906540. Accessed September 22, 2014.",
    "Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc.; March 2019.",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Rexulti (brexpiprazole) [prescribing information]. Deerfield, IL: Lundbeck; December 2021.",
    "Prescribing information. Mirvaso (brimonidine). Fort Worth, TX: Galderma Laboratories, L.P., August 2013.",
    "Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” J AAPOS, 2003, 7(1):69-70. [PubMed 12690374].",
    "Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” Pediatr Emerg Care, 2008, 24(3):167-9. [PubMed 18347496].",
    "Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” J Pediatr, 2001, 138(3):441-3. [PubMed 11241061].",
    "Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” J AAPOS, 2001, 5(5):281-4. [PubMed 11641636].",
    "Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996;16(5):323-327. [PubMed 8869767].",
    "Ozkardesler S, Gurpinar T, Akan M, et al. A possible perianesthetic serotonin syndrome related to intrathecal fentanyl. J Clin Anesth. 2008;20(2):143-145. [PubMed 18410872].",
    "Sandyk R. L-dopa induced “serotonin syndrome” in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol. 1986;6(3):194-195. [PubMed 3711372].",
    "Jang SH, Nam JH, Lee J, Chang MC. Takotsubo cardiomyopathy associated with serotonin syndrome in a patient with stroke: A case report. Medicine (Baltimore). 2019;98(13):e15057. [PubMed 30921235].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "D.H.E. 45 (dihydroergotamine mesylate) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals North America; September 2009.",
    "Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017.",
    "Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.",
    "Gerfen CR. Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci. 2000;23(Suppl):S64-S70. [PubMed 11052222].",
    "Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. [PubMed 19886950].",
    "Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. [PubMed 18628446].",
    "Buprenorphine/naloxone sublingual film [prescribing information]. Princeton, NJ: Sandoz Inc.; June 2018.",
    "Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma LP; September 2018.",
    "U.S. Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004. Accessed Online July 8, 2014 at www.ncbi.nlm.nih.gov/books/NBK64245/. [PubMed 22514846].",
    "Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. [PubMed 28315808].",
    "Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. [PubMed 28972983].",
    "Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732-734. [PubMed 30140853].",
    "Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. [PubMed 23423407].",
    "Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885. [PubMed 25299603].",
    "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.",
    "Wellbutrin SR (bupropion hydrochloride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2017.",
    "Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety. 2001;13(1):50-52. [PubMed 11233461].",
    "Pamelor (nortriptyline) [prescribing information]. Hazelwood, MO: Mallinckrodt Inc; June 2014.",
    "Amitriptyline hydrochloride [prescribing information]. Princeton, NJ: Sandoz Inc; May 2014.",
    "Norpramin (desipramine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; November 2018.",
    "Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother. 2000;34(7):871-874. [PubMed 10928399].",
    "Baetz M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry. 1995;40(7):428-429. [PubMed 8548727].",
    "Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol. 1997;12(1):61-63. [PubMed 9179637].",
    "Morrison EK, Rowe AS. Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia. J Clin Pharm Ther. 2012;37(5):610-613. [PubMed 22452676].",
    "Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone. Psychosomatics. 1992;33(2):235-236. [PubMed 1557493].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Lamberg TS, Kivisto KT, Laitila J, Martensson K, Neuvonen PJ. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur J Clin Pharmacol. 1998;54(9-10):761-766. [PubMed 9923581].",
    "Vasostrict (vasopressin) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; March 2021.",
    "Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martin MA, Altimiras J. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res. 2009;23(12):1795-1796. [PubMed 19441067].",
    "Chen D, Klesmer J, Giovanniello A, Katz J. Mental status changes in an alcohol abuser taking valerian and gingko biloba. Am J Addict. 2002;11(1):75-77. [PubMed 11876586].",
    "Khom S, Baburin I, Timin E, et al. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology. 2007;53(1):178-187. [PubMed 17585957].",
    "Benke D, Barberis A, Kopp S, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009;56(1):174-181. [PubMed 18602406].",
    "Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998;280(18):1566-1567. [PubMed 9820254].",
    "Gutierrez S, Ang-Lee MK, Walker DJ, Zacny JP. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav. 2004;78(1):57-64. [PubMed 15159134].",
    "Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. 2004;18(10):831-836. [PubMed 15551388].",
    "Hallam KT, Olver JS, McGrath C, Norman TR. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Hum Psychopharmacol. 2003;18(8):619-625. [PubMed 14696021].",
    "Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23(3):260-268. [PubMed 12826988].",
    "Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426. [PubMed 15900287].",
    "Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(12):1333-1336. [PubMed 15328251].",
    "Wong SL, Cavanaugh J, Shi H, et al, “Effects of Divalproex Sodium on Amitriptyline and Nortriptyline Pharmacokinetics,” Clin Pharmacol Ther, 1996, 60(1):48-53. [PubMed 8689811].",
    "Vandel S, Bertschy G, Jounet JM et al, “Valpromide Increases the Plasma Concentrations of Amitriptyline and Nortriptyline in Depressive Patients,” Ther Drug Monit, 1988, 10(4):386-9. [PubMed 3144066].",
    "Fu C, Katzman M, Goldbloom DS, “Valproate/Nortriptyline Interaction,” J Clin Psychopharmacol, 1994, 14(3):205-6. [PubMed 8027418].",
    "Fehr C, Grunder G, Hiemke C, et al, “Increase in Serum Clomipramine Concentrations Caused by Valproate,” J Clin Psychopharmacol, 2000, 20(4):493-4. [PubMed 10917416].",
    "Prescribing information. Depakote (divalproex sodium). North Chicago, IL: Abbott Laboratories, April 2009.",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Viibryd (vilazodone) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.",
    "Heise CW, Malashock H, Brooks DE. A review of vilazodone exposures with focus on serotonin syndrome effects. Clin Toxicol (Phila). 2017;55(9):1004-1007. [PubMed 28594246].",
    "Laliberte B, Kishk OA. Serotonin syndrome in a pediatric patient after vilazodone ingestion. Pediatr Emerg Care. 2018;34(12):e226-e228. [PubMed 28350718].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndromes. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "ProAir Digihaler (albuterol sulfate) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; December 2022.",
    "Perforomist (formoterol fumarate) [prescribing information]. Morgantown, WV; Mylan Specialty LP; May 2019.",
    "Xopenex HFA (levalbuterol tartrate) [prescribing information]. Lake Forest, IL: Akorn Inc; January 2019.",
    "Serevent Diskus (salmeterol xinafoate) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2022.",
    "Brovana (arformoterol tartrate) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; May 2019.",
    "Arcapta (indacaterol) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2021.",
    "Striverdi Respimat (olodaterol) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; November 2021.",
    "Terbutaline [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; February 2021.",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Trintellix (vortioxetine) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; July 2019.",
    "Ong CY, Vasanwala FF. Diaphoresis: a presentation of serotonin syndrome from vortioxetine. Prim Care Companion CNS Disord. 2018;20(3):pii: 17l02191. [PubMed 29917334].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndromes. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Exxua (gepirone) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; September 2023.",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Weiner AL, Tilden FF Jr, McKay CA Jr. Serotonin syndrome: case report and review of the literature. Conn Med. 1997;61(11):717-721. [PubMed 9419960].",
    "Pinel-Rios JF, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Gillman PK. Serotonin syndrome - clomipramine too soon after moclobemide? Int Clin Psychopharmacol. 1997;12(6):339-342. [PubMed 9547136].",
    "Voirol P, Hodel PF, Zullino D, Baumann P. Serotonin syndrome after small doses of citalopram or sertraline. J Clin Psychopharmacol. 2000;20(6):713-714. [PubMed 11106153].",
    "Tomaselli G, Modestin J. Repetition of serotonin syndrome after reexposure to SSRI-- a case report. Pharmacopsychiatry. 2004;37(5):236-238. [PubMed 15359377].",
    "Tseng WP, Tsai JH, Wu MT, Huang CT, Liu HW. Citalopram-induced serotonin syndrome: a case report. Kaohsiung J Med Sci. 2005;21(7):326-328. [PubMed 16089311].",
    "Siguent Hycor (hydrocortisone) ophthalmic ointment [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; August 2013.",
    "Vistaril (hydroxyzine) [prescribing information]. New York, NY: Pfizer Inc; September 2019.",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Published December 19, 2019. Accessed December 19, 2019.",
    "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.",
    "Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98. [PubMed 26333030].",
    "Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. [PubMed 26063215].",
    "Muzzaale AD, Daubresse M, Bae S, Chu NM, Lentine KL, Segev DL, McAdams-DeMarco M. Benzodiazepines, codispensed opioids, and mortality among patients initiating long-term in-center hemodialysis. Clin J Am Soc Nephrol. 2020;15(6):794-804. [PubMed 32457228].",
    "Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. [PubMed 28315808].",
    "Silbert BS, Rosow CE, Keegan CR, et al. The effect of diazepam on induction of anesthesia with alfentanil. Anesth Analg. 1986;65(1):71-77. [PubMed 3079632].",
    "Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. [PubMed 28972983].",
    "Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732-734. [PubMed 30140853].",
    "Li Y, Delcher C, Wei Y-JJ, Reisfield GM, Brown JD, Tighe P, Winterstein AG. Risk of opioid overdose associated with concomitant use of opioid and skeletal muscle relaxants: a population-based cohort study. Clin Pharmacol Ther. 2020;108(1):81-89. [PubMed 32022906].",
    "Yang RM, Oh IS, Li J, Jeon HL, Shin JY. Association between opioid analgesic plus benzodiazepine use and death: a case-crossover study. J Psychosom Res. 2020;135:110153. [PubMed 32504894].",
    "Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. [PubMed 23423407].",
    "Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885. [PubMed 25299603].",
    "Moran KM, Calip GS, Lee TA, Koronkowski MJ, Lau DT, Schumock GT. Risk of fall-related injury and all-cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: a case-time-control analysis. [published online ahead of print] Pharmacotherapy. 2021. doi: 10.1002/phar.2612. [PubMed 34328644].",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Xospata (gilteritinib) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; November 2018.",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Seebri Neohaler (glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.",
    "Seebri Breezhaler (glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; July 2015.",
    "Utibron Neohaler (indacaterol and glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.",
    "Ultibro Breezhaler (indacaterol and glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; August 2014.",
    "Green HH, Ray L, Buchanan J, Matsler N. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis. Am J Health Syst Pharm. 2023;80(18):1234-1237. [PubMed 37348110].",
    "Qbrexza (glycopyrronium) [prescribing information]. Scottsdale, AZ: Journey Medical Corporation; October 2022.",
    "GlucaGen (glucagon) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; December 2011.",
    "Mitchell JR, Cavanaugh JH, Arias L, Oates JA. Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970;49(8):1596-1604. [PubMed 5431666].",
    "Mitchell JR, Arias L, Oates JA. Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. JAMA. 1967;202(10):973-976. [PubMed 5630743].",
    "Poe TE, Edwards JL, Taylor RB. Hypertensive crisis possibly due to drug interaction. Postgrad Med. 1979;66(5):235-237. [PubMed 493191].",
    "Fann WE, Cavanaugh JH, Kaufmann JS, et al. Doxepin: effects on transport of biogenic amines in man. Psychopharmacologia. 1971;22(2):111-125. [PubMed 5124185].",
    "Meyer JF, McAllister CK, Goldberg LI. Insidious and prolonged antagonism of guanethidine by amitriptyline. JAMA. 1970;213(9):1487-1488. [PubMed 5468457].",
    "Leishman AW, Matthews HL, Smith AJ. Antagonism of guanethidine by imipramine. Lancet. 1963;1(7272):112. [PubMed 13929453].",
    "Gulati OD, Dave BT, Gokhale SD, Shah KM. Antagonism of adrenergic neuron blockade in hypertensive subjects. Clin Pharmacol Ther. 1966;7(4):510-514. [PubMed 5939974].",
    "Ismelin (guanethidine) [summary of product characteristics]. Basildon, Essex, UK: Amdipharm UK Limited; July 2014.",
    "Briant RH, Reid JL, Dollery CT. Interaction between clonidine and desipramine in man. Br Med J. 1973;1(5852):522-523. [PubMed 4571186].",
    "Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. J Am Ger Soc. 1983;31(3):164-165. [PubMed 6827017].",
    "Cubeddu LX, Cloutier G, Gross K, et al, Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats. Clin Pharmacol Ther. 1984;35(5):576-584. [PubMed 6424997].",
    "Buckley M, Feely J. Antagonism of antihypertensive effect of guanfacine by tricyclic antidepressants. Lancet. 1991;337(8750):1173-1174. [PubMed 1674059].",
    "Keaney F, Crimlisk H, Bean J. Lofexidine and desipramine: interaction results in breakthrough opioid withdrawal symptoms. Int J Psychiatry Clin Pract. 2002;6(3):179-181. [PubMed 24945207].",
    "Stiff JL, Harris DB. Clonidine withdrawal complicated by amitriptyline therapy. Anesthesiology. 1983;59(1):73-74. [PubMed 6859615].",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.",
    "Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691. [PubMed 24549548].",
    "Lexapro (escitalopram) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.",
    "Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287].",
    "Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Dardennes RM, Even C, Ballon N, Bange F. Serotonin syndrome caused by a clomipramine-moclobemide interaction. J Clin Psychiatry. 1998;59(7):382-383. [PubMed 9714270].",
    "Benazzi F. Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry. 1996;29(4):162. [PubMed 8858717].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Adler AR, Charnin JA, Quraishi SA. Serotonin syndrome: the potential for a severe reaction between common perioperative medications and selective serotonin reuptake inhibitors. A A Case Rep. 2015;5(9):156-159. [PubMed 26528701].",
    "Hebant B, Guillaume M, Desbordes M, Gaillon G, Maltete D, Lefaucheur R. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Rev Neurol (Paris). 2016;172(12):788-789. [PubMed 27838092].",
    "Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J. Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy. J Clin Anesth. 2015;27(3):247-251. [PubMed 25499271].",
    "Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth. 2008;55(8):521-525. [PubMed 18676387].",
    "Priligy (dapoxetine) [Summary of Product Characteristics]. Wooburn Green, Buckinghamshire, United Kingdom: A. Menarini Farmaceutica Internazionale SRL; March 2019.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Quviviq (daridorexant) [prescribing information]. Radnor, PA: Idorsia Pharmaceuticals US Inc; January 2022.",
    "Garey KW, Ansden GW, Johns CA. Possible interaction between imipramine and butalbital. Pharmacotherapy. 1997;17:1041-1042. [PubMed 9324197].",
    "Alexanderson A, Price Evans DA, Joqvist F. Steady state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J. 1969;4:764. [PubMed 5391106].",
    "Burrows GD, Davies B. Antidepressants and barbiturates. Br Med J. 1971;4:113. [PubMed 5097405].",
    "Silverman G, Braithwaite R. Interaction of benzodiazepines and tricyclic antidepressants. Br Med J. 1972;4:111. [PubMed 4677890].",
    "Moody JP, Whyte SF, MacDonald AJ, et al. Pharmacokinetic aspects of protriptyline plasma levels. Eur J Clin Pharmacol. 1977;11:51. [PubMed 832658].",
    "Ishii M, Tatsuzawa Y, Yoshino A, Nomura S. Serotonin syndrome induced by augmentation of SSRI with methylphenidate. Psychiatry Clin Neurosci. 2008;62(2):246. [PubMed 18412855].",
    "Turkoglu S. Serotonin syndrome with sertraline and methylphenidate in an adolescent. Clin Neuropharmacol. 2015;38(2):65-66. [PubMed 25768857].",
    "Park YM, Jung YK. Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(4):719-720. [PubMed 20298736].",
    "Peyre H, Delorme R. A case of severe hyperthermia after administration of methylphenidate. J Clin Psychopharmacol. 2012;32(2):299-300. [PubMed 22388166].",
    "Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology. 1995;45(2):219-223. [PubMed 7854515].",
    "Concerta (methylphenidate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2017.",
    "Focalin XR (dexmethylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2019.",
    "Azstarys (serdexmethylphenidate and dexmethylphenidate) [prescribing information]. Grand Rapids, MI: Corium Inc; March 2021.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993;53(1):84-88. [PubMed 8257462].",
    "Dy P, Arcega V, Ghali W, Wolfe W. Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. BMJ Case Rep. 2017; pii: bcr-2017-221486. [PubMed 28784915].",
    "Kinoshita H, Ohkubo T, Yasuda M, Yakushiji F. Serotonin syndrome induced by dextromethorphan (Medicon) administrated at the conventional dose. Geriatr Gerontol Int. 2011;11(1):121-122. [PubMed 21166968].",
    "Tanaka A, Nagamatsu T, Yamaguchi M, et al. Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother. 2011;45(1):e1. [PubMed 21228393].",
    "Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol (Phila). 2008;46(8):771-773. [PubMed 19238739].",
    "Ganetsky M, Babu KM, Boyer EW. Serotonin syndrome in dextromethorphan ingestion responsive to propofol therapy. Pediatr Emerg Care. 2007;23(11):829-831. [PubMed 18007217].",
    "Manaboriboon B, Chomchai C. Dextromethorphan abuse in Thai adolescents: a report of two cases and review of literature. J Med Assoc Thai. 2005;88(Suppl 8):S242-S245. [PubMed 16856446].",
    "Navarro A, Perry C, Bobo WV. A case of serotonin syndrome precipitated by abuse of the anticough remedy dextromethorphan in a bipolar patient treated with fluoxetine and lithium. Gen Hosp Psychiatry. 2006;28(1):78-80. [PubMed 16377370].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Spravato (esketamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2019.",
    "Nichols AI, Abell M, Chen Y, Behrle JA, Frick G, Paul J. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol. 2013;28(2):99-105. [PubMed 23221858].",
    "Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559].",
    "Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-2491. [PubMed 18809731].",
    "Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018.",
    "Khedezla (desvenlafaxine) [prescribing information]. Marietta, GA: Osmotica Pharmaceutical US LLC; August 2017.",
    "Hamed M, Mitchell H, Clow DJ. Hyponatremic convulsion associated with desmopressin and imipramine treatment. BMJ. 1993;306(6886):1169. [PubMed 8499820].",
    "Nocdura (desmopressin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; June 2018.",
    "DDAVP (desmopressin) injectable [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; March 2018.",
    "DDAVP (desmopressin) nasal spray [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; March 2018.",
    "Desmopressin acetate tablets [prescribing information]. Newtown, PA: KVK-Tech, Inc.; February 2019.",
    "Henrich WL, Cronin R, Miller PD, Anderson RJ. Hypotensive sequelae of diazoxide and hydralazine therapy. JAMA. 1977;237(3):264-265. [PubMed 576161].",
    "Miller WE, Gifford RW Jr, Humphrey DC, Vidt DG. Management of severe hypertension with intravenous injections of diazoxide. Am J Cardiol. 1969;24(6):870-875. [PubMed 5360241].",
    "Mizroch S, Yurasek M. Hypotension and bradycardia following diazoxide and hydralazine therapy. JAMA. 1977;237(23):2471-2472. [PubMed 576958].",
    "Romberg GP, Lordon RE. Hypotensive sequelae of diazoxide and hydralazine therapy. JAMA. 1977;238(10):1025. [PubMed 577939].",
    "Proglycem (diazoxide) [prescribing information]. Miami, FL: IVAX Pharmaceuticals Inc; October 2003.",
    "Vibrocil nasal drops, nasal gel, nasal spray, and microdoser (dimetindene maleate/phenylephrine base) [prescribing information]. Petach-Tikva, Israel: Promedico Ltd; November 1998.",
    "Korsuva (difelikefalin) [prescribing information]. Stamford, CT: Cara Therapeutics, Inc; August 2021.",
    "Prescribing information. Diclegis (doxylamine/pyridoxine). Bryn Mawr, PA: Duchesnay USA, Inc., 4/2013.",
    "Cesamet (nabilone) [product monograph]. Quebec, Canada: Valeant Canada Ltd; December 2009.",
    "Benowitz NL,Jones RT. Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades. Clin Pharmacol Ther. 1977;21(3):336-342. [PubMed 837652].",
    "Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60(6):1303-1314. [PubMed 11152013].",
    "Freemon FR, Rosenblatt JE, El-Yousef MK. Interaction of physostigmine and delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther. 1975;17(2):121-6. [PubMed1091392].",
    "Multaq (dronedarone) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2014.",
    "Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45(5):371-377. [PubMed 15345781].",
    "van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29(1):9-15. [PubMed 19142100].",
    "Noordam R, van den Berg ME, Niemeijer MN, et al. Assessing prolongation of the heart rate corrected QT interval in users of tricyclic antidepressants: advice to use Fridericia rather than Bazett's correction. J Clin Psychopharmacol. 2015;35(3):260-265. [PubMed 25856783].",
    "Droperidol injection [prescribing information]. Shirley, NY: American Regent Inc.; January 2009.",
    "Lamberg JJ, Gordin VN. Serotonin syndrome in a patient with chronic pain polypharmacy. Pain Med. 2014;15(8):1429-1431. [PubMed 22925399].",
    "Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. J Clin Psychopharmacol. 2015;35(4):382-388. [PubMed 26082973].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; December 2017.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-1491. [PubMed 18809731].",
    "Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007;63(2):159-163. [PubMed 16680561].",
    "Sensipar (cinacalcet) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; March 2019.",
    "Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol. 1999;12(1):7-10. [PubMed 10447148].",
    "Dannawi M. Possible serotonin syndrome after combination of buspirone and St John's Wort. J Psychopharmacol. 2002;16(4):401. [PubMed 12503845].",
    "Parker V, Wong AH, Boon HS, Seeman MV. Adverse reactions to St John's wort. Can J Psychiatry. 2001;46(1):77-79. [PubMed 11221494].",
    "Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy. 2000;20(5):568-574. [PubMed 10809344].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Boinpally R, Gad N, Gupta S, Periclou A. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin Ther. 2014;36(11):1638-1649. [PubMed 25236915].",
    "Chen G, Lee R, Hojer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727-36. [PubMed 23975654].",
    "Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2016.11. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopscyhiatry. 1996:29(4):156-158. [PubMed 8858715].",
    "Khalili H, Dashti-Khavidaki S, Amini S, Mousavi M. Recurrence of panic attacks after brucellosis treatment--highly probable citalopram and rifampin drug interaction. J Clin Psychopharmacol. 2012;32(6):842-844. [PubMed 23131874].",
    "Kukoyi O, Argo TR, Carnahan RM. Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram. Pharmacotherapy. 2005;25(3):435-437. [PubMed 15843291].",
    "Prescribing information. Intermezzo (zolpidem). Point Richmond, CA: Transcept Pharmaceuticals, Inc., November 2011.",
    "Prescribing information. Edluar (zolpidem). Somerset, NJ: Meda Pharmaceuticals Inc., 10/10.",
    "Prescribing information. Ambien (zolpidem). Bridgewater, NJ: sanofi-aventis U.S. LLC, August 2010.",
    "Zurzuvae (zuranolone) [prescribing information]. Cambridge, MA: Biogen Inc; August 2023.",
    "Kadar D. Letter: Amitriptyline and isoproterenol: fatal drug combination. Can Med Assoc J. 1975;112(5):556-557. [PubMed 1116081].",
    "Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973;1(5849):311-315. [PubMed 4685619].",
    "Pohl R, Yeragani VK, Balon R. Effects of isoproterenol in panic disorder patients after antidepressant treatment. Biol Psychiatry. 1990;28(3):203-214. [PubMed 2165824].",
    "Isuprel (iosoproterenol) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; October 2022.",
    "Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022.",
    "Anon. Higdon J et al: Linus Pauling Institute. Available from: https://tinyurl.com/2p86msf7 [Accessed February 3, 2023].",
    "Worthley LIG. Clinical toxicology: part 1. Diagnosis and management of common drug overdosage. Crit Care Resusc. 2002;4(3):192-215. [PubMed 16573429].",
    "Nakajo M, Shapiro B, Sisson JC, Swanson DP, Beierwaltes WH. Salivary gland accumulation of meta-[131I]iodobenzylguanidine. J Nucl Med. 1984;25(1):2-6. [PubMed 6726418].",
    "Estorch M, Carrio I, Mena E, et al. Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur J Nucl Med Mol Imaging. 2004;31(12):1575-1580. [PubMed 15221292].",
    "Azedra (iobenguane I 131) [prescribing information]. New York, NY: Progenics Pharmaceuticals Inc; July 2018.",
    "AdreView (iobenguane I 123) [prescribing information]. Arlington Heights, IL: GE Healthcare; March 2020.",
    "Omnipaque (iohexol) [prescribing information]. Malborough, MA: GE Healthcare Inc; February 2022.",
    "Iomeron (iomeprol) [summary of product characteristics]. Sydney, New South Wales: Bracco Pty Ltd; February 2009.",
    "Isovue-M (iopamidol) [prescribing information]. Princeton, NJ: Bracco Diagnostics Inc; January 2017.",
    "Bagheri H, Picault P, Schmitt L, Houin G, Berlan M, Montastruc JL. Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants. Br J Clin Pharmacol. 1994;37(1):93-96. [PubMed 8148228].",
    "Vay M, Meyer MJ, Blank A, et al. Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial. Clin Pharmacokinet. 2020;59(7):927-939. [PubMed 32060866].",
    "Owen JA, Nakatsu SL, Fenemore J, Condra M, Surridge DH, Morales A. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol. 1987;32(6):577-582. [PubMed 3653227].",
    "Guthrie SK, Hariharan M, Grunhaus LJ. Yohimbine bioavailability in humans. Eur J Clin Pharmacol. 1990;39(4):409-411. [PubMed 2076728].",
    "Prescribing information. Atrovent HFA (ipratropium). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., October 2011.",
    "Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.",
    "Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125(11):940-941. [PubMed 8967683].",
    "Toohey TP, Lu BY, Wada C. Toxic effects of psychotropics related to possible p450 enzyme inhibition by kava: report of 2 cases. Prim Care Companion CNS Disord. 2013;15(5):PCC.13br01539. [PubMed 24511438].",
    "Perez J, Holmes JF. Altered mental status and ataxia secondary to acute kava ingestion. J Emerg Med. 2005;28(1):49-51. [PubMed 15657005].",
    "Gurley BJ, Swain A, Hubbard MA, et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008;83(1):61-69. [PubMed 17495878].",
    "Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426. [PubMed 15900287].",
    "Sarris J. LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35. [PubMed 21073405].",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.",
    "Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691. [PubMed 24549548].",
    "Lexapro (escitalopram) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.",
    "Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, Yilmaz U. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol. 2004;34(5):262-268. [PubMed 15231861].",
    "Kitagawa K, Kawada K, Morita S, et al. Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer. Ann Oncol. 2012;23(3):743-747. [PubMed 21690231].",
    "Ardalan B, Subbarayan PR, Ramos Y, et al. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res. 2010;16(11):3019-3027. [PubMed 20501625].",
    "Kim H-H, An SH, Cho YH, Kim S-Y, Lee HG, Yoon SY. Oxaliplatin-induced torsades de pointes and long QT syndrome in a patient with gastric cancer. Acta Oncol. 2013;52(6):1223-1224. [PubMed 23368679].",
    "Chung LW, Liao Y-M, Hsieh C-Y, Lin C-Y. Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma. Acta Oncol. 2009;48(1):156-157. [PubMed 18618340].",
    "Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40(4):303-307. [PubMed 20529041].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "De la Fuente JM, Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol Psychiatry. 1992;32(4):369-374. [PubMed 1420651].",
    "Gerson GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. Postgrad Med J. 1977, 53(Suppl 4):104-9. [PubMed 304576].",
    "Anafranil (clomipramine) [prescribing information]. Ontario, Canada: Patheon, Inc.; March 2019.",
    "Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.",
    "Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc.; October 2013.",
    "Chen HK, Hsieh CJ. Risk of gastrointestinal hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: a retrospective cohort study. Schizophr Res. 2018;195:237-244. [PubMed 29107449].",
    "Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal 'slow gut' reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699-709. [PubMed 28623627].",
    "Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019;33(1):81-91. [PubMed 30456745].",
    "George J, Hotham R, Melton W, Chapple K. Clozapine-induced stercoral colitis: a surgical perspective. BMJ Case Rep. 2019;12(8). pii: e227718. [PubMed 31471354].",
    "Rodrigues A, Duarte A, Marques A, et al. Multiple spontaneous small bowel perforations due to clozapine-case report. Int J Surg Case Rep. 2018;53:262-264. [PubMed 30447547].",
    "Osterman MT, Foley C, Matthias I. Clozapine-induced acute gastrointestinal necrosis: a case report. J Med Case Rep. 2017;11(1):270. [PubMed 28938913].",
    "Pautola L, Hakala T. Medication-induced acute esophageal necrosis: a case report. J Med Case Rep. 2016;10(1):267. [PubMed 27679991].",
    "Osseis M, Lim C, Lahat E, Doussot A, Salloum C, Azoulay D. Hepatic venous outflow block caused by compressive fecaloma in a schizophrenic patient treated with clozapine. Drug Discov Ther. 2015;9(6):422-423. [PubMed 26781928].",
    "Martinez Diaz-Caneja C, Gonzalez-Molinier M, Conejo Galindo J, Moreno Iniguez M. Severe bowel ischemia due to clozapine with complete remission after withdrawal. J Clin Psychopharmacol. 2010;30(4):463-465. [PubMed 20631566].",
    "McKinnon ND, Azad A, Waters BM, Joshi KG. Clozapine-induced bowel infarction: a case report. Psychiatry (Edgmont). 2009;6(3):30-35. [PubMed 19724752].",
    "Leung JS, Lee CC, Lee WK, Kwong PP. Rapidly fatal clozapine-induced intestinal obstruction without prior warning signs. Aust N Z J Psychiatry. 2008;42(12):1073-1074. [PubMed 19031643].",
    "Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatry. 2008;16(3):216-219. [PubMed 18568631].",
    "Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry. 2006;6:43. [PubMed 17052340].",
    "Pelizza L, De Luca P, La Pesa M, Borella D. Clozapine-induced intestinal occlusion: a serious side effect. Acta Biomed. 2007;78(2):144-148. [PubMed 17933283].",
    "Oke V, Schmidt F, Bhattarai B, et al. Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report. Int Med Case Rep J. 2015;8:189-192. [PubMed 26392790].",
    "Yu SC, Chen HK, Lee SM. Rapid development of fatal bowel infarction within 1 week after clozapine treatment: a case report. Gen Hosp Psychiatry. 2013;35(6):679.e5-e6. [PubMed 24199785].",
    "Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206(1-3):e31-e36. [PubMed 20719440].",
    "Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry. 2006;6:43. [PubMed 17052340].",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems. Https://www.fda.gov/safety/medical-product-safety-information/clozaril-fazaclo-odt-versacloz-clozapine-drug-safety-communication-fda-strengthens-warning-untreated. Published January 28, 2020. Accessed January 31, 2020.",
    "Clozaril (clozapine) [prescribing information]. Rosemont, PA: HLS Therapeutics USA Inc; March 2020.",
    "Xiang YT, Chiu HF, Ungvari GS, et al. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009. Hum Psychopharmacol. 2015;30(2):94-99. [PubMed 25611192].",
    "Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry. 2001;179:167-171. [PubMed 11483480].",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. Br Med J. 1973;1(5849):311-315. [PubMed 4685619].",
    "Ghose K. Assessment of peripheral adrenergic activity and its interactions with drugs in man. Eur J Clin Pharmacol. 1980;17(4):233-238. [PubMed 6105078].",
    "Ghose K, Rama Rao VA, Bailey J, Coppen A. Antidepressant activity and pharmacological interactions of ciclazindol. Psychopharmacology (Berl). 1978;57(1):109-114. [PubMed 96461].",
    "Svedmyr N. The influence of a tricyclic antidepressive agent (protriptyline) on some circulatory effects of noradrenaline and adrenaline in man. Life Sci. 1968;7(1):77-84. [PubMed 5636628].",
    "Mitchell JR, Cavanaugh JH, Arias L, Oates JA. Guanethidine and related agents. III. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970;49(8):1596-1604. [PubMed 5431666].",
    "Gershon S, Holmberg G, Mattsson E, Mattsson N, Marshall A. Imipramine hydrochloride. Its effects on clinical, autonomic and psychological functions. Arch Gen Psychiatry. 1962;6(1):96-101. [PubMed 13898068].",
    "Boakes AJ, Laurence DR, Lovel KW, O'Neil R, Verrill PJ. Adverse reactions to local anaesthetic-vasoconstrictor preparations. A study of the cardiovascular responses to Xylestin and Hostacain-with-Adrenaline. Br Dent J 1972;133(4):137-140. [PubMed 4507157].",
    "Imipramine [prescribing information]. Fairfield, NJ: Excellium Pharmaceutical Inc; October 2012.",
    "Phenylephrine hydrochloride. [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2012.",
    "Kovanaze (tetracaine and oxymetazoline) nasal spray [prescribing information]. Fort Collins, CO: St Renatus LLC; June 2016.",
    "Reyvow (lasmiditan) [prescribing information]. Indianapolis, IN: Lilly USA LLC; October 2019.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Sinemet (carbidopa levodopa) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; July 2014.",
    "Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844-1850. [PubMed 16958094].",
    "Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry. 1976;128:490-493. [PubMed 1276554].",
    "Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997;7(3):207-212. [PubMed 9213080].",
    "Mamo DC, Sweet RA, Mulsant BH, et al. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. Am J Geriatr Psychiatry. 2000;8(3):226-231. [PubMed 10910421].",
    "Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: A review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17(5):377-389. [ PubMed 9315989].",
    "Messerli FH, Frohlich ED. High blood pressure: A side effect of drugs, poisons, and food. Arch Intern Med. 1979;139(6):682-687. [PubMed 375859].",
    "Goldberg LI. Dopamine receptors and hypertension: Physiologic and pharmacologic implications. Am J Med. 1984;77(4A):37-44. [PubMed 6148892].",
    "Prange AJ Jr, McCurdy RL, Cochrane CM. The systolic blood pressure response of depressed patients to infused norepinephrine. J Psychiatr Res. 1967;5(1):1-13. [PubMed 20034172].",
    "Levotuss (levodropropizine) [summary of product characteristics]. Barcelona, Spain: Rottapharm SL; December 2013.",
    "Zyplo (levodropropizine) [summary of product characteristics]. Rio de Janeiro, Brazil: Bago Laboratories of Brazil SA; June 2014.",
    "Levopront (levodropropizine) [summary of product characteristics]. Lugano, Switzerland: Novintethical; January 2014.",
    "Gatti G, Barzaghi N, Dominijanni R, Cordaro C, Perucca E. Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. Drugs Exp Clin Res. 1993;19(1):33-39. [PubMed 8223138].",
    "Recorlev (levoketoconazole) [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.; January 2022.",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm. Published March 22, 2016. Accessed March 24, 2016.",
    "Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. Psychosomatics. 2009;50(6):638-639. [PubMed 19996237].",
    "Kumai M, Maeda Y, Miura M, et al. Serotonin syndrome developing immediately after the initiation of low-dose methadone therapy: a case report. Case Rep Oncol. 2020;13(1):281-284. [PubMed 32308591].",
    "Mancano MA, Esordi MV, Patel DD, Milenki KJ. ISMP adverse drug reactions: longitudinal thumbnail fissures due to erlotinib priapism associated with the use of ExtenZe blindness from a nevirapine-based HAART regimen hyperprolactinemia and galactorrhea due to aripiprazole trypophobia associated with gabapentin coadministered linezolid and methadone cause serotonin syndrome. Hosp Pharm. 2019;54(2):88-92. [PubMed 30923400].",
    "Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. Pharmacotherapy. 2015;35(1):112-117. [PubMed 25615513].",
    "Dvir Y, Smallwood P. Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry. 2008;30(3):284-287. [PubMed 18433663].",
    "McCue RE, Joseph M. Venlafaxine- and trazodone-induced serotonin syndrome. Am J Psychiatry. 2001;158(12):2088-2089. [PubMed 11729039].",
    "Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. J Palliat Med. 2006;9(6):1257-1259. [PubMed 17187532].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-441. [PubMed 16051647].",
    "Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.",
    "Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019.",
    "Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis. 2003;36(9):1197. [PubMed 12715317].",
    "Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. J Am Med Dir Assoc. 2004;5(2):111-113. [PubMed 14984623].",
    "Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. 2006;26(2):269-276. [PubMed 16466332].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Clomipramine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; May 2019.",
    "Desipramine [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; January 2019.",
    "Nortriptyline [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; June 2019.",
    "Trimipramine [prescribing information]. Boca Raton, FL: Breckenridge Pharmaceutical, Inc.; July 2017.",
    "Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of Linezolid With Risk of Serotonin Syndrome in Patients Receiving Antidepressants. JAMA Netw Open. 2022;5(12):e2247426. [PubMed 36534400].",
    "Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data. J Antimicrob Chemother. 2012;67(2):494-502. [PubMed 22139199].",
    "Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents. Int J Antimicrob Agents. 2023;62(1):106843. [PubMed 37160238].",
    "Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43(2):180-187. [PubMed 16779744].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Dopergin (lisuride) [summary of product characteristics]. North Shore, Auckland, New Zealand: Bayer New Zealand Limited; April 2013.",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Belviq (lorcaserin) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; May 2017.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Sensipar (cinacalcet) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; March 2019.",
    "Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007;63(2):159-163. [PubMed 16680561].",
    "Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos. 2008;36(12):2484-1491. [PubMed 18809731].",
    "Dormagen (lormetazepam) [summary of product characteristics]. West Yorkshire, UK: Genus Pharmaceuticals; August 2016.",
    "Keaney F, Crimlisk H, Bean J. Lofexidine and desipramine: interaction results in breakthrough opioid withdrawal symptoms. Int J Psychiatry Clin Pract. 2002;6(3):179-181. [PubMed 24945207].",
    "Briant RH, Reid JL, Dollery CT. Interaction between clonidine and desipramine in man. Br Med J. 1973;1(5852):522-523. [PubMed 4571186].",
    "Hui KK. Hypertensive crisis induced by interaction of clonidine with imipramine. J Am Ger Soc. 1983;31(3):164-165. [PubMed 6827017].",
    "Cubeddu LX, Cloutier G, Gross K, et al, Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats. Clin Pharmacol Ther. 1984;35(5):576-584. [PubMed 6424997].",
    "Stiff JL, Harris DB. Clonidine withdrawal complicated by amitriptyline therapy. Anesthesiology. 1983;59(1):73-74. [PubMed 6859615].",
    "Dollery CT, Reid JL. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. Arzneimittelforschung. 1982;32(8a):984-987. [PubMed 6890374].",
    "Lucemyra (lofexidine) [prescribing information]. Louisville, KY: US WorldMeds, LLC; May 2018.",
    "BritLofex (lofexidine) [summary of product characteristics]. Berkshire, UK: Britannia Pharmaceuticals; August 2015.",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Caplyta (lumateperone) [prescribing information]. New York, NY: Intra-Cellular Therapies, Inc.; April 2022.",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. J Neuropsychiatry Clin Neurosci. 2012;24(4):E52. [PubMed 23224488].",
    "Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. Ann Pharmacother. 2002;36(10):1647-1648. [PubMed 12243617 ].",
    "Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. Med J Aust. 1995;162(10):554. [PubMed 7776924].",
    "Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991;337(8735):246. [PubMed 1670882].",
    "Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care. 2014;21(1):108-113. [PubMed 24052457].",
    "Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French Pharmacovigilance Database. J Clin Psychopharmacol. 2105;35(4):382-388. [PubMed 26082973].",
    "Alkhatib AA, Peterson KA, Tuteja AK. Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. Dig Dis Sci. 2010;55(1):215-216. [PubMed 19165596].",
    "Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ. Cardiac surgery in a patient taking monoamine oxidase inhibitors: an adverse fentanyl reaction. Anesth Analg. 1994;78(3):593-597. [PubMed 8109782].",
    "Ailawadhi S, Sung KW, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther. 2007;32(2):199-202. [PubMed 17381671].",
    "Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med. 2010;38(4):447-480. [PubMed 18757161].",
    "Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL. Meperidine-induced serotonin syndrome in a susceptible patient. Br J Anaesth. 2009;103(3):369-370. [PubMed 19556270].",
    "Das PK, Warkentin DI, Hewko R, Forrest DL. Serotonin syndrome after concomitant treatment with linezolid and meperidine. Clin Infect Dis. 2008;46(2):264-265. [PubMed 18171260].",
    "Tissot TA. Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. Anesthesiology. 2003;98(6):1511-1512. [PubMed 12766667].",
    "Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol. 1981;1(5):319-321. [PubMed 7334144].",
    "Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. Clin Neuropharmacol. 2004;27(3):150-151. [PubMed 15190240].",
    "Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor. Am J Case Rep. 2014;15:562-564. [PubMed 25540831].",
    "El-Okdi NS, Lumbrezer D, Karanovic D, Ghose A, Assaly R. Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. Am J Ther. 2014;21(4):e97-e99. [PubMed 24158007].",
    "Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. Age Ageing. 2011;40(4):528. [PubMed 21414947].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.",
    "Ultram (tramadol hydrochloride) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2017.",
    "Surmaitis RM, Nappe TM, Cook MD. Serotonin syndrome associated with therapeutic metaxalone in a patient with cirrhosis. Am J Emerg Med. 2016;34(2):e5-e6. [PubMed 26159819].",
    "Martini DI, Nacca N, Haswell D, Cobb T, Hodgman M. Serotonin syndrome following metaxalone overdose and therapeutic use of a selective serotonin reuptake inhibitor. Clin Toxicol (Phila). 2015;53(3):185-187. [PubMed 25671244].",
    "Bosak AR, Skolnik AB. Serotonin syndrome associated with metaxalone overdose. J Med Toxicol. 2014;10(4):402-405. [PubMed 24805103].",
    "Skelaxin (metaxalone) [prescribing information]. Bristol, TN: King Pharmaceuticals Inc; March 2018.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Ng BK, Cameron AJ, Liang R, Rahman H. Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review. Can J Anaesth. 2008;55(1):36-41. [PubMed 18166746].",
    "Schwiebert C, Irving C, Gillman PK. Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. Anaesthesia. 2009;64(8):924. [PubMed 19604213].",
    "Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol. 1999;13(3):313-317. [PubMed 10512094].",
    "Pollack G, Pollack A, Delfiner J, Fernandez J. Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use. Laryngoscope. 2009;119(10):1941-1946. [PubMed 19598213].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Nicolaou G, Lee D. Methylene blue-induced serotonin syndrome presenting with ocular clonus and failure of emergence from general anesthesia. Can J Anaesth. 2016;63(7):896-897. [PubMed 26943644].",
    "Zuschlag ZD, Warren MW, K Schultz S. Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics. 2018;59(6):539-546. [PubMed 30104021].",
    "Clomipramine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; May 2019.",
    "Desipramine [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc.; January 2019.",
    "Nortriptyline [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; June 2019.",
    "Trimipramine [prescribing information]. Boca Raton, FL: Breckenridge Pharmaceutical, Inc.; July 2017.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.",
    "Nozinan (methotrimeprazine) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc.; February 2020.",
    "Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.",
    "Tolvon (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.",
    "Lumin (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.",
    "Clemmesen L, Mikkelsen PL, Lund H, Bolwig TG, Rafaelsen OJ. Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels. Psychopharmacology (Berl). 1984;82(4):348-354. [PubMed 6427827].",
    "Kopera H. Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo. Br J Clin Pharmacol. 1978;5 Suppl 1:29S-34S. [PubMed 341941].",
    "Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490].",
    "Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581].",
    "Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976].",
    "Walia C, Gupta R, Kaur M, Mahajan L, Kaur G, Kaur B. Propofol sparing effect of dexmedetomidine and magnesium sulfate during BIS targeted anesthesia: A prospective, randomized, placebo controlled trial. J Anaesthesiol Clin Pharmacol. 2018;34(3):335-340. [PubMed 30386016].",
    "Yoldas H, Yildiz I, Karagoz I, et al. Effects of bispectral index-controlled use of magnesium on propofol consumption and sedation level in patients undergoing colonoscopy. Medeni Med J. 2019;34(4):380-386. [PubMed 32821465].",
    "Chen J, Qian K, Liu CH., Li XL, Chen Y, Wang JQ. Effects of intravenous administration of magnesium sulfate in propofol-based sedation for ERCP in elderly patients: a randomized, double-blind, placebo-controlled study. BMC Geriatr. 2023;23(1):413. [PubMed 37420201].",
    "McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345].",
    "Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282].",
    "Magnesium sulfate [prescribing information] injection. Lake Zurich, IL: Fresenius Kabi; September 2021.",
    "Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira, Inc; July 2022.",
    "Myrbetriq (mirabegron extended-release) [prescribing information]. Northbrook, IL: Astellas Pharm US Inc; June 2012.",
    "Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008;77(5):643-650. [PubMed 18350762].",
    "Molsidain (molsidomine) [summary of product characteristics]. Barcelona, Spain; Sanofi-Aventis SA; August 2013.2. Molsiton (molsidomine) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501832. Accessed September 1, 2014.",
    "Xywav (calcium, magnesium, potassium, and sodium oxybates) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; July 2020.",
    "Xyrem (sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; July 2020.",
    "Flivas (naftopidil) [summary of product characteristics]. Tokyo, Japan: Asahi Kasei Pharma Corporation; September 2014.",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Margolese HC, Chouinard G. Serotonin syndrome from addition of low-dose trazodone to nefazodone. Am J Psychiatry. 2000;157(6):1022. [PubMed 10831493].",
    "Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49(448):871-874. [PubMed 10818650].",
    "Peak DA. Toxic effects of nefazodone. Ann Emerg Med. 1997;30(4):551. [PubMed 9326874].",
    "Fogelson DL. Nefazodone- and/or sodium tetradecyl sulfate-associated leukopenia, fever, and shaking chills in a patient with premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997;17(3):222-223. [PubMed 9169968].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Ikorel (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.",
    "Ikorel (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: Sanofi-Aventis Australia Pty Ltd; July 2014.",
    "Dry mouth and delayed dissolution of nitroglycerin. N Engl J Med. 1984;310(17):1122-1123. [PubMed 6424013].",
    "Robbins LJ. Dry mouth and delayed dissolution of sublingual nitroglycerin. N Engl J Med. 1983;309(16):985. [PubMed 6413859].",
    "Sato H, Koretsune Y, Taniguchi T, et al. Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial. Arzneimittelforschung. 1997;47(2):128-131. [PubMed 9079231].",
    "Nitrostat (nitroglycerin) sublingual tablets [prescribing information]. New York, NY: Pfizer Inc; May 2011.",
    "Bernard JM, Moren J, Demeure D, Hommeril JL, Passuti N, Pinaud M. Diltiazem reduces the dose requirement for nitroprusside-induced hypotension. Anesth Analg. 1993;77(2):318-323. [PubMed 8346832].",
    "Nitropress (nitroprusside) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2015.",
    "Sermion (nicergoline) [BR prescribing information]. Sao Paulo, Brazil. Pfizer Ltda; November 2015.",
    "Sermion 10 mg (nicergoline) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199700555. Accessed December 17, 2015.",
    "Gazyva (obinutuzumab) [prescribing information]. South San Francisco, CA: Genentech Inc; November 2013.",
    "Zeposia (ozanimod) [prescribing information]. Summit, NJ: Celgene Corporation; March 2020.",
    "Tran JQ, Zhang P, Walker S, et al. Multiple-dose pharmacokinetics of ozanimod and its major active metabolites and the pharmacodynamic and pharmacokinetic interactions with pseudoephedrine, a sympathomimetic agent, in healthy subjects [published online October 6, 2020]. Adv Ther. Doi: 10.1007/s12325-020-01500-0. [PubMed 33025342].",
    "Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014.",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.",
    "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.",
    "Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98. [PubMed 26333030].",
    "Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study [published online June 10, 2015]. BMJ. doi: 10.1136/bmj.h2698. [PubMed 26063215].",
    "Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. [PubMed 28315808].",
    "Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. [PubMed 28972983].",
    "Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732-734. [PubMed 30140853].",
    "Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. [PubMed 23423407].",
    "Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885. [PubMed 25299603].",
    "Roxicodone (oxycodone) [prescribing information]. Newport, KY: Xanodyne Pharmaceuticals Inc; March 2009.",
    "Targiniq ER (oxycodone/naloxone) extended-release tablets [prescribing information]. Stamford CT: Purdue Pharma LP; July 2014.",
    "Oxycontin (oxycodone) extended-release tablets [prescribing information]. Stamford CT: Purdue Pharma LP; August 2015.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.",
    "Patanase (olopatadine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2021.",
    "Ryaltris (olopatadine and mometasone) [prescribing information]. Columbus, OH: Hikma Specialty USA Inc.; January 2022.",
    "Norgesic (orphenadrine and paracetamol) [summary of product characteristics]. Chatswood, New South Wales, Australia: iNova Pharmaceuticals (Australia) Pty Limited; January 2014.",
    "Paraldehyde injection BP [product monograph]. Montreal, QC: Omega Laboratories Ltd; February 2011.",
    "Weiner AL, Tilden FF Jr, McKay CA Jr. Serotonin syndrome: case report and review of the literature. Conn Med. 1997;61(11):717-721. [PubMed 9419960].",
    "Shioda K, Nisijima K, Nishida S, Kato S. Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants. Hum Psychopharmacol. 2004;19(5):353-354. [PubMed 15252829].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Paxil (paroxetine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; January 2017.",
    "Clarissa Samara V, Warner J. Rare case of severe serotonin syndrome leading to bilateral compartment syndrome. BMJ Case Rep. 2017; pii: bcr2016218842. [PubMed 28258180].",
    "Hebant B, Guillaume M, Desbordes M, et al. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Rev Neurol (Paris). 2016;172(12):788-789. [PubMed 27838092].",
    "Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol. 2010;24(10):1433-1438. [PubMed 19423610].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndromes. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology (Berl). 2000;147(4):378-383. [PubMed 10672631].",
    "Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. Paroxetine shifts imipramine metabolism. Psychiatry Res. 1996;59(3):189-196. [PubMed 8930024].",
    "Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993;44(4):349-355. [PubMed 8513845].",
    "Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008].",
    "Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol. 2009;49(2):219-228. [PubMed 19001559].",
    "Ghaemi SN, Kirkwood CK. Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine. J Clin Psychopharmacol. 1998;18(4):342-343. [PubMed 9690702].",
    "Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011;67(6):591-599. [PubMed 21161196].",
    "PegIntron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.",
    "Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691. [PubMed 24549548].",
    "Lexapro (escitalopram) [prescribing information]. Irvine, CA: Allergan USA Inc; January 2017.?7. Nebot N, Arkenau H-T, Infante JR, et al. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018;84(4):764-775. [PubMed 29243287].",
    "Waliany S, Zhu H, Wakelee H, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16(12):2029-2039. [PubMed 34418561].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Trental (pentoxifylline) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2015.",
    "Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; July 2017.",
    "Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.",
    "Wakix (pitolisant) [prescribing information]. Plymouth Meeting, PA: Harmony Biosciences, LLC; August 2019.",
    "Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.",
    "Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.",
    "Suflave (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride) [prescribing information]. Holbrook, MA: Braintree Laboratories, Inc.; June 2023.",
    "GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Novel Laboratories, Inc.; March 2022.",
    "GoLYTELY (polyehtylene glycol 3350 and electrolytes) [prescribing information]. May 2021.",
    "Moviprep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2022.",
    "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; May 2021.",
    "Mirapex (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2021.",
    "Symlin (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2015.",
    "Matulane (procarbazine) [prescribing information]. Wilmington, NC: Alcami Corporation; August 2018.",
    "Hebant B, Guillaume M, Desbordes M, Gaillon G, Maltete D, Lefaucheur R. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Rev Neurol (Paris). 2016;172(12):788-789. [PubMed 27838092].",
    "Suphanklang J, Santimaleeworagun W, Supasyndh O. Combination of escitalopram and rasagiline induced serotonin syndrome: a case report and review literature. J Med Assoc Thai. 2015;98(12):1254-1257. [PubMed 27004312].",
    "Duval F, Flabeau O, Razafimahefa J, Spampinato U, Tison F. Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome. Mov Disord. 2013;28(10):1464. [PubMed 23495033].",
    "Hisham M, Sivakumar MN, Nandakumar V, Lakshikanthcharan S. Linezolid and rasagiline - a culprit for serotonin syndrome. Indian J Pharmacol. 2016;48(1):91-92. [PubMed 26997732].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Azilect (rasagiline) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; December 2018.",
    "Azilect (rasagiline) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; February 2022.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Yupelri (revefenacin) [prescribing information]. Morgantown, WV: Mylan Specialty LP; November 2018.",
    "Prescribing information. MS Contin (morphine). Stamford, CT: Purdue Pharma L.P., July 2012.",
    "Prescribing information. Oxycontin (oxycodone). Stamford, CT: Purdue Pharma L.P., 04/2013.",
    "Prescribing information. Zohydro ER (hydrocodone). San Diego, CA: Zogenix, Inc., 10/2013.",
    "Prescribing information. Exalgo (hydromorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2013.",
    "Clark K, Lam LT, Agar M, Chye R, Currow DC. The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. Palliat Med. 2010;24(4):410-8. [PubMed 20348271].",
    "Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-88. [PubMed 18422378].",
    "Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis ",
    "Requip XL (ropinirole) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2021.",
    "BESREMi (ropeginterferon alfa-2b) [prescribing information]. Burlington, MA: PharmaEssentia USA Corporation; November 2021.",
    "Neupro (rotigotine) [prescribing information]. Smyrna, GA: UCB Inc; July 2021.",
    "Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2011.",
    "Xadago (safinamide) [prescribing information]. Louisville, KY: US WorldMeds LLC; June 2017.",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Garcia-Monco JC, Padierna A, Gomez Beldarrain M. Selegiline, fluoxetine, and depression in Parkinson's disease. Mov Disord. 1995;10(3):352. [PubMed 7651457].",
    "Richard IH, Kulan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48(4):1070-1077. [PubMed 9109902].",
    "Hebant B, Guillaume M, Desbordes M, Gaillon G, Maltete D, Lefaucheur R. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Rev Neurol (Paris). 2016;172(12):788-789. [PubMed 27838092].",
    "Suphanklang J, Santimaleeworagun W, Supasyndh O. Combination of escitalopram and rasagiline induced serotonin syndrome: a case report and review literature. J Med Assoc Thai. 2015;98(12):1254-1257. [PubMed 27004312].",
    "Hisham M, Sivakumar MN, Nandakumar V, Lakshmikanthcharan S. Linezolid and rasagiline - a culprit for serotonin syndrome. Indian J Pharmacol. 2016;48(1):91-92. [PubMed 26997732].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Valenzuela JE, Weiner K, Saad C. Cholinergic stimulation of human pancreatic secretion. Dig Dis Sci. 1986;31(6):615-619. [PubMed 2872022].",
    "Kuvshinoff BW, Demar AR, James L, McFadden DW, Fink AS. Effect of pancreatic denervation and atropine on the pancreatic response to secretin. Pancreas. 1993;8(5):609-614. [PubMed 8302798].",
    "Park HS, Lee YL, Kwon HY, Chey WY, Park HJ. Significant cholinergic role in secretin-stimulated exocrine secretion in isolated rat pancreas. Am J Physiol. 1998;274(2 pt 1):G413-G418. [PubMed 9486197].",
    "Chey WY, Chang TM. Neural control of the release and action of secretin. J Physiol Pharmacol. 2003;54(suppl 4):105-112. [PubMed 15075453].",
    "Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.",
    "Garcia-Monco JC, Padierna A, Gomez Beldarrain M. Selegiline, fluoxetine, and depression in Parkinson's disease. Mov Disord. 1995;10(3):352. [PubMed 7651457].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997;48(4):1070-1077. [PubMed 9109902].",
    "Pinel-Rios JF, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Gillman PK. Serotonin syndrome - clomipramine too soon after moclobemide? Int Clin Psychopharmacol. 1997;12(6):339-342. [PubMed 9547136].",
    "Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84-90. [PubMed 9262938].",
    "Zelapar (selegiline) orally disintegrating tablets [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; July 2014.",
    "Selegiline capsules [prescribing information]. Saddle Brook, NJ: Rising Pharmaceuticals Inc; April 2019.",
    "Emsam (selegiline) transdermal system [prescribing information]. Morgantown, WV: Mylan Specialty LP; July 2017.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. Ann Pharmacother. 2002;36(10):1647-1648. [PubMed 12243617].",
    "Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. J Clin Psychopharmacol. 2015;35(4):382-388. [PubMed 26082973].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Effexor XR (venlafaxine extended release) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; December 2017.",
    "Pristiq (desvenlafaxine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; February 2018.",
    "Fetzima (levomilacipran) [prescribing information]. Irvine, CA: Allergan USA Inc; December 2017.",
    "Savella (milnacipran) [prescribing information]. Irvine, CA: Allergan USA Inc; December 2017.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204. [PubMed 20673553].",
    "Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006;21(1):49-56. [PubMed 16317317].",
    "Serdolect (sertindole) [summary of product characteristics]. Valby, Denmark: Lundbeck AS; March 2021.",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Likasitwattanakul S. Serotonin syndrome: a case report. J Med Assoc Thai. 2005;88(7):993-996. [PubMed 16241032].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; December 2017.",
    "Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. 2006;26(2):269-276. [PubMed 16466332].",
    "Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. Clin Neuropharmacol. 2004;27(3):150-151. [PubMed 15190240].",
    "Bonin B, Vandel P, Vandel S, Sechter D, Bizouard P. Serotonin syndrome after sertraline, buspirone and loxapine? Therapie. 1999;54(2):269-271. [PubMed 10394270].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndromes. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Kurtz DL, Bergstrom RF, Goldberg MJ, et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther. 1997;62(2):145-56. [PubMed 9284850].",
    "Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14(2):90-98. [PubMed 8195463].",
    "Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997;17(4):284-291. [PubMed 9241008].",
    "Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry. 1993;150(7):1125-1126. [PubMed 8317590].",
    "Barros J, Asnis G. An interaction of sertraline and desipramine. Am J Psychiatry. 1993;150(11):1751. [PubMed 8214190].",
    "Solai LK, Mulsant BH, Pollock BG, et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry. 1997;58(10):440-443. [PubMed 9375595].",
    "Rapaflo (silodosin) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2020.",
    "Belsomra (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2020.",
    "Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490].",
    "Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581].",
    "Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976].",
    "Walia C, Gupta R, Kaur M, Mahajan L, Kaur G, Kaur B. Propofol sparing effect of dexmedetomidine and magnesium sulfate during BIS targeted anesthesia: A prospective, randomized, placebo controlled trial. J Anaesthesiol Clin Pharmacol. 2018;34(3):335-340. [PubMed 30386016].",
    "Yoldas H, Yildiz I, Karagoz I, et al. Effects of bispectral index-controlled use of magnesium on propofol consumption and sedation level in patients undergoing colonoscopy. Medeni Med J. 2019;34(4):380-386. [PubMed 32821465].",
    "Chen J, Qian K, Liu CH., Li XL, Chen Y, Wang JQ. Effects of intravenous administration of magnesium sulfate in propofol-based sedation for ERCP in elderly patients: a randomized, double-blind, placebo-controlled study. BMC Geriatr. 2023;23(1):413. [PubMed 37420201].",
    "McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345].",
    "Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282].",
    "Magnesium sulfate [prescribing information] injection. Lake Zurich, IL: Fresenius Kabi; September 2021.",
    "Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira, Inc; July 2022.",
    "Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone G. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet. 1990;19(3):241-255. [PubMed 2394063].",
    "John VA, Luscombe DK, Kemp H. Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics of clomipramine and its desmethyl metabolite during chronic dosing. J Int Med Res. 1980;8(suppl 3):88-95. [PubMed 7202824].",
    "de Jong C, Drubbel I, Roelfs S, Harmsze A. Clomipramine toxicity in a CYP 2D6 poor metabolizer patient who suddenly stopped smoking. J Clin Psychopharmacol. 2018;38(4):389-391. [PubMed 29894392].",
    "Terao T, Ohmori O, Shinkai T. A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration. Acta Psychiatr Scand. 1999;99(5):388-390. [PubMed 10353456].",
    "Luscombe DK, John V. Influence of age, cigarette smoking and the oral contraceptive on plasma concentrations of clomipramine. Postgrad Med J. 1980;56(suppl 1):99-102. [PubMed 7393836].",
    "Vazquez-Rodriguez AM, Arranz Pena MI, Lopez Ibor JJ, et al. Clomipramine test: serum level determination in three groups of psychiatric patients. J Pharm Biomed Anal. 1991;9(10-12):949-952. [PubMed 1822217].",
    "Anafranil (clomipramine) [prescribing information]. Ontario, Canada: Patheon, Inc.; March 2019.",
    "Prescribing information. Thalidomid (thalidomide). Summit, NJ: Celgene Corporation, February 2013.",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Harrigan EP, Miceli JJ, Anziano R, et al. A Randomized evaluation of the effects of six antipsychotic agents on the QTc, in the absence and presence of the metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62-69. [PubMed 14709949].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31(6):347-353. [PubMed 8685072].",
    "Balant-Gorgia AE, Ries C, Balant LP. Metabolic interaction between fluoxetine and clomipramine: a case report. Pharmacopsychiatry. 1996;29(1):38-41. [PubMed 8852534].",
    "Anafranil (clomipramine) [prescribing information]. Webster Groves, MO: Mallinckrodt Pharmaceuticals; September 2017.",
    "Prescribing information. Spiriva (tiotropium). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., March 2012.",
    "Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013.",
    "Annex III relevant sections of the summary of product characteristics and package leaflet. Mydocalm (tolperisone hydrochloride) [prescribing information]. Meyrin, Switzerland: Labatec Pharma SA; October 2013.",
    "Dalmadi B, Leibinger J, Szeberenyi S, et al. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003:31(5):631-636. [PubMed 12695352].",
    "Topamax (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2011.",
    "Qsymia (phentermine/topiramate) [prescribing information]. Mountain View, CA: Vivus Inc; July 2012.",
    "Panectyl (trimeprazine) [product monograph]. Montreal, Quebec, Canada: ERFA Canada 2012 Inc; December 2015.",
    "Trelstar (triptorelin) [prescribing information]. Bloomington, IN: Baxter Pharmaceutical Solutions, LLC; December 2018.",
    "Trelstar (triptorelin) [product monograph]. Montreal, Quebec, Canada: Knight Therapeutics Inc.; September 2022.",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657].",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Fluphenazine [prescribing information]. Paramus, NJ: TWi Pharmaceuticals USA, Inc.; January 2022.",
    "Abilify (aripiprazole) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2020.",
    "Secuado (asenapine) [prescribing information]. Miami, FL: Noven Therapeutics, LLC; October 2019.",
    "Rexulti (brexpiprazole) [prescribing information]. Deerfield, IL: Lundbeck; December 2021.",
    "Vraylar (cariprazine) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2019.",
    "Clozapine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; July 2020.",
    "Fanapt (iloperidone) [prescribing information]. Rockville, MD: Vanda Pharmaceuticals Inc.; December 2010.",
    "Caplyta (lumateperone) [prescribing information]. New York, NY: Intra-Cellular Therapies, Inc.; April 2022.",
    "Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; December 2019.",
    "Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC: October 2019.",
    "Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2021.",
    "Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.",
    "Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021.",
    "Geodon (ziprasidone) [prescribing information]. New York, NY: Pfizer Inc.; January 2022.",
    "Dysport (abobotulinumtoxinA) [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals Inc; November 2018.",
    "Xeomin (incobotulinumtoxinA) [prescribing information]. Raleigh, NC: Merz Pharmaceuticals, LLC; July 2018.",
    "Botox (onabotulinumtoxinA) [prescribing information]. Irvine, CA: Allergan Pharmaceuticals; May 2018.",
    "Jeuveau (prabotulinumtoxinA) [prescribing information]. Santa Barbara, CA: Evolus Inc; February 2019.",
    "Daxxify (daxibotulinumtoxinA-lanm) [prescribing information]. Newark, CA: Revance Therapeutics, Inc.; September 2022.",
    "Incruse Ellipta (umeclidinium) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2014.",
    "Anoro Ellipta (umeclidinium and vilanterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.",
    "Incruse Ellipta (umeclidinium) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; November 2015.",
    "Fexinidazole [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2021.",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Fintepla (fenfluramine) [prescribing information]. Emeryville, CA: Zogenix, Inc.; June 2020.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Luvox CR (fluvoxamine) [prescribing information].Palo Alto, CA: Jazz Pharmaceuticals Inc; January 2017.",
    "Baetz M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry. 1995;40(7):428-429. [PubMed 8548727].",
    "Demers JC, Malone M. Serotonin syndrome induced by fluvoxamine and mirtazapine. Ann Pharmacother. 2001;35(10):1217-1220. [PubMed 11675850].",
    "Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother. 2006;40(1):155-157. [PubMed 16368927].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndromes. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31(6):347-353. [PubMed 8685072].",
    "Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry. 1996;57(6):257-264. [PubMed 8666564].",
    "Conus P, Bondolfi G, Eap CB, Macciardi F, Baumann P. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopsychiatry. 1996;29(3):108-110. [PubMed 8738315].",
    "Seifritz E, Holsboer-Trachsler E, Hemmeter U, Eap CB, Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol. 1994;4(1):15-20. [PubMed 8204992].",
    "Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15(3):243-246. [PubMed 8333005].",
    "Spina E, Pollicino AM, Avenoso A, Campo GM, Caputi AP. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int J Clin Pharmacol Res. 1993;13(3):167-171. [PubMed 8225700].",
    "Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit. 1992;14(3):194-196. [PubMed 1412604].",
    "Xu ZH, Huang SL, Zhou HH. Inhibition of imipramine N-demethylation by fluvoxamine in Chinese young men. Zhongguo Yao Li Xue Bao. 1996;17(5):399-402. [PubMed 9863158].",
    "Maskall DD, Lam RW. Increased plasma concentration of imipramine following augmentation with fluvoxamine. Am J Psychiatry. 1993;150(10):1566. [PubMed 8379574].",
    "Flunarizine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.",
    "Rohypnol [prescribing information]. Rio de Janeiro RJ, Brasil: Roche Chemicals and Pharmaceuticals SA; May 2014.",
    "Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.",
    "Molaie M. Serotonin syndrome presenting with migraine like stroke. Headache. 1997;37(8):519-521. [PubMed 9329236].",
    "Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84-90. [PubMed 9262938].",
    "Pinel-Rios FJ, Penuelas-Calvo I, Cerezo-Ramirez N, Hamad-Cueto O, Garcia-Casares N. Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report. Actas Esp Psiquiatr. 2016;44(5):193-202. [PubMed 27644101].",
    "Nisijima K. Serotonin syndrome overlapping with neuroleptic malignant syndrome: A case report and approaches for differentially diagnosing the two syndromes. Asian J Psychiatr. 2015;18:100-101. [PubMed 26506919].",
    "Heritier Barras AC, Walder B, Seeck M. Serotonin syndrome following methylene blue infusion: a rare complication of antidepressant therapy. J Neurol Neurosurg Psychiatry. 2010;81(12):1412-1413. [PubMed 20547626].",
    "Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005;60(9):934-935. [PubMed 16115263].",
    "Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. [PubMed 12927331].",
    "Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247(10):811. [PubMed 11127542].",
    "Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; March 2017.",
    "Smith DL, Wenegrat BG. A case report of serotonin syndrome associated with combined nefazodone and fluoxetine. J Clin Psychiatry. 2000;61(2):146. [PubMed 10732666].",
    "George TP, Godleski LS. Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry. 1996;39(5):384-385. [PubMed 8704074].",
    "Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry. 1986;21(11):1067-1071. [PubMed 3488767].",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndromes. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14(2):90-98. [PubMed 8195463].",
    "Wilens TE, Biederman J, Baldessarini RJ, McDermott SP, Puopolo PR, Flood JG. Fluoxetine inhibits desipramine metabolism. Arch Gen Psychiatry. 1992;49(9):752. [PubMed 1514882].",
    "Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51(3):239-248. [PubMed 1544284].",
    "Suckow RF, Roose SP, Cooper TB. Effect of fluoxetine on plasma desipramine and 2-hydroxydesipramine. Biol Psychiatry. 1992;31(2):200-204. [PubMed 1737080].",
    "von Ammon Cavanaugh S. Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics. 1990;31(3):273-276. [PubMed 2388981].",
    "DeMaso DR, Hunter TA. Combining fluoxetine with desipramine. J Am Acad Child Adolesc Psychiatry. 1990;29(1):151. [PubMed 2295572].",
    "Michals M, Stanley DA, Crismon ML, Barrow NE. Elevated tricyclic antidepressant plasma concentrations associated with fluoxetine: two case reports. J Neuropsychiatry Clin Neurosci. 1990;2(4):466-467. [PubMed 2136405].",
    "Goodnick PJ. Influence of fluoxetine on plasma levels of desipramine. Am J Psychiatry. 1989;146(4):552. [PubMed 2784633].",
    "Bell IR, Cole JO. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol. 1988;8(6):447-448. [PubMed 3266222].",
    "Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology. 1992;25(4):202-207. [PubMed 1454161].",
    "Rosenstein DL, Takeshita J, Nelson JC. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose. Am J Psychiatry. 1991;148(6):807. [PubMed 2035725].",
    "Benazzi F. Venlafaxine-fluoxetine-nortriptyline interaction. J Psychiatry Neurosci. 1997;22(4):278-279. [PubMed 9262050].",
    "Kahn DG. Increased plasma nortriptyline concentration in a patient cotreated with fluoxetine. J Clin Psychiatry. 1990;51(1):36. [PubMed 2295592].",
    "Schraml F, Benedetti G, Hoyle K, Clayton A. Fluoxetine and nortriptyline combination therapy. Am J Psychiatry. 1989;146(12):1636-1637. [PubMed 2589560].",
    "Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA. 1997;277(21):1682. [PubMed 9169893].",
    "el-Yazigi A, Chaleby K, Gad A, Raines DA. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol. 1995;35(1):17-21. [PubMed 7751409].",
    "Muller N, Brockmoller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. Ther Drug Monit. 1991;13(6):533-536. [PubMed 1771652].",
    "March JS, Moon RL, Johnston H. Fluoxetine-TCA interaction. J Am Acad Child Adolesc Psychiatry. 1990;29(6):985-986. [PubMed 2273036].",
    "Balant-Gorgia AE, Ries C, Balant LP. Metabolic interaction between fluoxetine and clomipramine: a case report. Pharmacopsychiatry. 1996;29(1):38-41. [PubMed 8852534].",
    "Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res. 1995;31(6):347-353. [PubMed 8685072].",
    "Sternbach H. Fluoxetine-clomipramine interaction. J Clin Psychiatry. 1995;56(4):171-172. [PubMed 7713858].",
    "Paul KL, Bhatara VS. Anticholinergic delirium possibly associated with protriptyline and fluoxetine. Ann Pharmacother. 1997;31(10):1260-1261. [PubMed 9337456].",
    "Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; October 2021.",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657].",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Fluanxol (flupentixol) [Canadian product monograph]. Montreal, QC, Canada: Lundbeck Canada Inc.; April 2014.",
    "Abilify (aripiprazole) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2020.",
    "Secuado (asenapine) [prescribing information]. Miami, FL: Noven Therapeutics, LLC; October 2019.",
    "Rexulti (brexpiprazole) [prescribing information]. Deerfield, IL: Lundbeck; December 2021.",
    "Vraylar (cariprazine) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2019.",
    "Clozapine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; July 2020.",
    "Fanapt (iloperidone) [prescribing information]. Rockville, MD: Vanda Pharmaceuticals Inc.; December 2010.",
    "Caplyta (lumateperone) [prescribing information]. New York, NY: Intra-Cellular Therapies, Inc.; April 2022.",
    "Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; December 2019.",
    "Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC: October 2019.",
    "Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2021.",
    "Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.",
    "Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021.",
    "Geodon (ziprasidone) [prescribing information]. New York, NY: Pfizer Inc.; January 2022.",
    "Bonnet U, Taazimi B, Montag M, et al. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015;27(4):424-425. [PubMed 26609657]",
    "Schmitz A, Botner B, Hund M. Bupropion with clozapine: case reports of seizure after coadministration. J Pharm Pract. 2021;34(3):497-502. [PubMed 32079452].",
    "Rucker J, Cook M. A case of prolonged seizure after ECT in a patient treated with clomipramine, lithium, L-tryptophan, quetiapine, and thyroxine for major depression. J ECT. 2008;24(4):272-274. [PubMed 18648320].",
    "Haberfellner EM. Myoclonic and generalized tonic clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55-56. [PubMed 11918994].",
    "Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother. 2002;36(3):437-439. [PubMed 11895056].",
    "Malek-Ahmadi P. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1988;33(1):76-77. [PubMed 3129174].",
    "Deshauer D, Albuquerque J, Alda M, Grof P. Seizures caused by possible interaction between olanzapine and clomipramine. J Clin Psychopharmacol. 2000;20(2):283-284. [PubMed 10770480].",
    "Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32(6):463-464. [PubMed 3121163].",
    "Fluphenazine [prescribing information]. Paramus, NJ: TWi Pharmaceuticals USA, Inc.; January 2022.",
    "Abilify (aripiprazole) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2020.",
    "Secuado (asenapine) [prescribing information]. Miami, FL: Noven Therapeutics, LLC; October 2019.",
    "Rexulti (brexpiprazole) [prescribing information]. Deerfield, IL: Lundbeck; December 2021.",
    "Vraylar (cariprazine) [prescribing information]. Madison, NJ: Allergan USA, Inc.; May 2019.",
    "Clozapine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; July 2020.",
    "Fanapt (iloperidone) [prescribing information]. Rockville, MD: Vanda Pharmaceuticals Inc.; December 2010.",
    "Caplyta (lumateperone) [prescribing information]. New York, NY: Intra-Cellular Therapies, Inc.; April 2022.",
    "Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; December 2019.",
    "Zyprexa (olanzapine) [prescribing information]. Indianapolis, IN: Lilly USA, LLC: October 2019.",
    "Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2021.",
    "Seroquel (quetiapine) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2022.",
    "Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021.",
    "Geodon (ziprasidone) [prescribing information]. New York, NY: Pfizer Inc.; January 2022.",
    "Covonia Dry Cough (pholcodine) solution [summary of product characteristics]. Huddersfield, United Kingdom: Thornton and Ross Ltd; April 2016.",
    "Baldo BA, Fisher MM, Pham NH. On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective. Clin Exp Allergy. 2009;39(3):325-344. [PubMed 19187323].",
    "Sinemet (carbidopa levodopa) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; July 2014.",
    "Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844-1850. [PubMed 16958094].",
    "Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry. 1976;128:490-493. [PubMed 1276554].",
    "Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997;7(3):207-212. [PubMed 9213080].",
    "Mamo DC, Sweet RA, Mulsant BH, et al. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. Am J Geriatr Psychiatry. 2000;8(3):226-231. [PubMed 10910421].",
    "Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: A review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17(5):377-389. [PubMed 9315989].",
    "Messerli FH, Frohlich ED. High blood pressure: A side effect of drugs, poisons, and food. Arch Intern Med. 1979;139(6):682-687. [PubMed 375859].",
    "Goldberg LI. Dopamine receptors and hypertension: Physiologic and pharmacologic implications. Am J Med. 1984;77(4A):37-44. [PubMed 6148892].",
    "Prange AJ Jr, McCurdy RL, Cochrane CM. The systolic blood pressure response of depressed patients to infused norepinephrine. J Psychiatr Res. 1967;5(1):1-13. [PubMed 20034172].",
    "Osmoprep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) [prescribing information]. Morrisville, NC: Salix Pharmaceuticals, Inc; November 2018.",
    "Steiner E, Dumont E, Spina E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther. 1988;43(5):577-581. [PubMed 3365919].",
    "Donovan JL, DeVane CL, Boulton D, Dodd S, Markowitz JS. Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food Chem Toxicol. 2003;41(8):1199-1201. [PubMed 12842189].",
    "Ayesh R, Dawling S, Hayler A, et al. Comparative effects of the diastereoisomers quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality. 1991;3(1):14-18. [PubMed 2039678].",
    "Qualaquin (quinine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2014. ",
    "Welldorm (cloral betaine) [summary of product characteristics]. Marlborough, Wiltshire, United Kingdom: Marlborough Pharmaceuticals Ltd; December 2014.",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. Clin Pharmacol Ther. 1984;35(6):852-855. [PubMed 6734038].",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet. 1982;2(8307):1059-1061. [PubMed 6127542].",
    "Alsop WR, Moore JG, Rollins DE, Tolman KG. The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate. J Clin Pharmacol. 1984;24(5-6):235-239. [PubMed 6747020].",
    "Cuvposa (glycopyrrolate). Atlanta, GA: Mikart Inc; February 2018.5. Dartisla ODT (glycopyrrolate) orally disintegrating tablets [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC: December 2021.",
    "Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016. ",
    "Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009. ",
    "Shprecher D, Sloan CT, Sederholm B. Neuropsychiatric side effects of cyclobenzaprine. BMJ Case Rep. 2013; pii: bcr2013008997. [PubMed 23645641].",
    "Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. Anesth Analg. 2006;103(6):1466-1468. [PubMed 17122225].",
    "Day LT, Jeanmonod RK. Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report. Am J Emerg Med. 2008;26(9):1069.e1-1069.e3. [PubMed 19091289].",
    "Flexeril (cyclobenzaprine) [prescribing information]. Titusville, NJ: McNeil Pediatrics; April 2013.",
    "Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112-1120. [PubMed 15784664].",
    "Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. [PubMed 12925718].",
    "Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. [PubMed 2035713].",
    "Curry SH, De Vane CL, Wolfe MM. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol. 1985;29:429-433. [PubMed 3912187].",
    "Amsterdam JD, Brunswick DJ, Potter L, et al. Cimetidine-induced alterations in desipramine plasma concentrations. Psychopharmacology. 1984;83:373-375. [PubMed 6436867].",
    "Abernethy DR, Todd EL. Doxepin-cimetidine interaction: increased bioavailability during cimetidine treatment. J Clin Psychopharmacol. 1986;6:8-12. [PubMed 3950073].",
    "Sutherland DL, Remillard AJ, Haight KR, et al. The influence of cimetidine versus ranitidine on doxepin pharmacokinetics. Eur J Clin Pharmacol. 1987;32:159-164. [PubMed 3582480].",
    "Wells BG, Pieper JA, Self TH, et al. The effect of ranitidine and cimetidine on imipramine disposition. Eur J Clin Pharmacol. 1986;31:285-290. [PubMed 379426].",
    "Henauer SA, Hollister LE. Cimetidine interaction with imipramine and nortriptyline. Clin Pharmacol Ther. 1984;35:183-187. [PubMed 6692646].",
    "Abernethy DR, Greenblatt DJ, Shader RI. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. J Pharmacol Exp Ther. 1984;229(3):702-705. [PubMed 6726654].",
    "Brown MA, Haight KR, McKay G. Cimetidine-doxepin interaction. J Clin Psychopharmacol. 1985;5:245-247. [PubMed 4019813].",
    "Shapiro PA. Cimetidine-imipramine interaction: case report and comments. Am J Psychiatry. 1984;141:152. [PubMed 6691449].",
    "Miller DD, Macklin M. Cimetidine-imipramine interaction: a case report. Am J Psychiatry. 1983;140:351. [PubMed 6829810].",
    "Miller DD, Sawyer JB, Duffy JP. Cimetidine’s effect on steady-state serum nortriptyline concentrations. Drug Intell Clin Pharm. 1983;17(12):904-905. [PubMed 6653407].",
    "Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther. 1987;42:278-282. [PubMed 3621787].",
    "Algiron (cimetropium) tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200900846. Accessed January 12, 2017. ",
    "Urocit-K (potassium citrate) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; December 2009.",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. Clin Pharmacol Ther. 1984;35(6):852-855. [PubMed 6734038].",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet. 1982;2(8307):1059-1061. [PubMed 6127542].",
    "Alsop WR, Moore JG, Rollins DE, Tolman KG. The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate. J Clin Pharmacol. 1984;24(5-6):235-239. [PubMed 6747020].",
    "Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015. ",
    "Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol. 1997;17(1):15-21. [PubMed 9004052].",
    "Giardina EG, Bigger Jr JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation. 1979;60(5):1045-1052. [PubMed 487538].",
    "Leonard HL, Meyer MC, Swedo SE, et al. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1460-1468. [PubMed 8543513].",
    "Braftovi (encorafenib) [prescribing information]. Boulder, CO: Array BioPharma Inc; October 2023.",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Kristalose (lactulose) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; July 2018.",
    "Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014.",
    "Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663].",
    "Visser L, Penning-van Beest F, Wilson J, et al. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon. Br J Clin Pharmacol. 2004;57(4):522-524. [PubMed 15025752].",
    "Andersson M, Lindh J, Mannheimer B. The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: A novel use of population based drug registers. J Clin Pharmacol. 2013;53(12):1322-1327. [PubMed 24038065].",
    "Rai R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol. 2015;5(Suppl 1):S29-S36. [PubMed 26041954].",
    "Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21(1):95-110. [PubMed 17223499].",
    "Enulose (lactulose) [prescribing information]. Morristown, NJ: Actavis Inc.; January 2011.",
    "Visser L, Penning-van Beest F, Wilson J, et al. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon. Br J Clin Pharmacol. 2004;57(4):522-524. [PubMed 15025752].",
    "Andersson M, Lindh J, Mannheimer B. The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: A novel use of population based drug registers. J Clin Pharmacol. 2013;53(12):1322-1327. [PubMed 24038065].",
    "Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.",
    "Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909].",
    "Generlac (lactulose) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals Inc; January 2014.",
    "Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663].",
    "Pirotte J, Guffens JM, Devos J. Comparative study of basal arterial ammonemia and of orally-induced hyperammonemia in chronic portal systemic encephalopathy, treated with neomycin, lactulose, and an association of neomycin and lactulose. Digestion. 1974;10(6):435-444. [PubMed 4448315].",
    "Weber FL Jr, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology. 1982;82(2):213-217. [PubMed 7054022].",
    "Weber FL Jr, Banwell JG, Fresard KM, Cummings JH. Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin. J Lab Clin Med. 1987;110(3):259-263. [PubMed 3611949].",
    "Capocaccia L, Riggio O. Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other? Hepatology. 1990;12(2):368-370. [PubMed 2391075].",
    "Martin AJ. Portal systemic encephalopathy--should lactulose and neomycin be used together. Br J Clin Pract. 1981;35(9):323-324. [PubMed 7326185].",
    "Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118].",
    "Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol. 2006;62(6):463-472. [PubMed 16758263].",
    "Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother. 2005;49(12):4903-4910. [PubMed 16304151].",
    "Tayrouz Y, Ganssmann B, Ding R, et al. Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther. 2001;70(5):405-414. [PubMed 11719726].",
    "Mikus G, Schmidt L, Burhenne J, et al. Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. Clin Pharmacokinet. 2004;43(14):1015-1024. [PubMed 15530130].",
    "U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).",
    "Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-58[PubMed 15365656].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-16. [PubMed 20394022].",
    "Raschi E, Poluzzi E, Godman B, et al. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One. 2013;8(11):e81208. [PubMed 24278396].",
    "Blom MT, Bardai A, van Munster BC, et al. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One. 2011;6(9):e23728. [PubMed 21961030].",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol. 2006;62(6):463-472. [PubMed 16758263].",
    "U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).",
    "Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-58[PubMed 15365656].",
    "Callreus T, Lundahl J, Hoglund P, Bengtsson P. Changes in gastrointestinal motility influence the absorption of desmopressin. Eur J Clin Pharmacol. 1999;55(4):305-309. [PubMed 10424324].",
    "Irribow (ramosetron) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200905270. Accessed June 17, 2016.",
    "U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).",
    "Kinevac (sincalide) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc.; December 2018.",
    "Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68(3):231-237. [PubMed 11014404].",
    "Skarke C, Jarrar M, Schmidt H, et al. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics. 2003;13(11):651-660. [PubMed 14583678].",
    "Kim TE, Lee H, Lim KS, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014;78(3):556-564. [PubMed 24602137].",
    "Vandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P. Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. J Pharm Pharmacol. 2010;62(4):401-412. [PubMed 20604828].",
    "Choo EF, Kurnik D, Muszkat M, et al. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther. 2006;317(3):1012-1018. [PubMed 16537797].",
    "Loperamide [prescribing information]. Morgantown, WA: Mylan Pharmaceuticals Inc; October 2016.",
    "Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-432. [PubMed 28281228].",
    "Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. [PubMed 23716032].",
    "Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010;5(4):E8-16. [PubMed 20394022].",
    "van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347-354. [PubMed 19523015].",
    "Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251-264. [PubMed 29201344].",
    "Vandael E, Vandenberk B, Willems R, Reyntens J, Vandenberghe J, Foulon V. Risk management of hospitalized psychiatric patients taking multiple QTc-prolonging drugs. J Clin Psychopharmacol. 2017;37(5):540-545. [PubMed 28817488].",
    "Meid AD, von Medem A, Heider D, et al. Investigating the additive interaction of QT-prolonging drugs in older people using claims data. Drug Saf. 2017;40(2):133-144. [PubMed 27896662].",
    "U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).",
    "Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother. 2002;50(6):1081-1084. [PubMed 12461038].",
    "Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 2002;53 Suppl 1:31S-36S. [PubMed 11879257].",
    "Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999;65(4):369-376. [PubMed 10223772].",
    "Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin ",
    "Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals, Inc; May 2015.",
    "U.S. Food and Drug Administration. Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm505303.htm (accessed 6/9/2016).",
    "Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60(8):575-58[PubMed 15365656].",
    "Huupponen R, Seppala P, Iisalo E. Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol. 1984;26:279-28[PubMed 6327318].",
    "Reissell P, Manninen V. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides. Acta Med Scand Suppl. 1982;668:88-90. [PubMed 6963097].",
    "Johnson BF, Rodin SM, Hoch K, et al. The effect of dietary fiber on the bioavailability of digoxin in capsules. J Clin Pharmacol. 1987;27:487-490. [PubMed 2821081].",
    "Nordstrom M, Melander A, Robertsson E, et al. Influence of wheat bran and of a bulk-forming ispaghula cathartic on the bioavailability of digoxin in geriatric in-patients. Drug Nutr Interact. 1987;5:67-69. [PubMed 3038494].",
    "Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation. 1978;58:164-172. [PubMed 647881].",
    "Huo G-W, Zuo R, Song Y, et al. Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: a meta-analysis. Open Med (Wars). 2021;16(1):728-736. [PubMed 34013044].",
    "Kostine M, Mauric E, Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474-484. [PubMed 34649118].",
    "Pederzoli F, Bandini M, Raggi D, et al. Is there a detrimental effect of antibiotic therapy in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab? Eur Urol. 2021;80(3):319-322. [PubMed 34053782].",
    "Kim JH, Ahn B, Hong S-M, et al. Parameters for treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors. [published online ahead of print] Cancer Res Treat. 202doi:10.4143/crt.2020.1198. [PubMed 34176250].",
    "Guven DC, Acar R, Yekeduz E, et al. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. [published online ahead of print] Curr Probl Cancer. 202doi: 10.1016/j.currproblcancer.2021.100760. [PubMed 34130864].",
    "Ishiyama Y, Tsunenori K, Nemoto Y, et al. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma. [published online ahead of print] Urol Oncol. 202doi: 10.1016/j.urolonc.2021.05.033. [PubMed 34284929].",
    "Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7(11):e1507670. [PubMed 30377571].",
    "Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437-1444. [PubMed 29617710].",
    "Geum MJ, Kim C, Kang JE, et al. Broad-spectrum antibiotic regimen affects survival in patients receiving nivolumab for non-small cell lung cancer. Pharmaceuticals (Basel). 2021;14(5):445. [PubMed 34066877].",
    "Derosa L, Routy B, Fidelle M, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78(2):195-206. [PubMed 32376136].",
    "Krief JO, de Tauriers PH, Dumenil C, et al. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. J Immunother Cancer. 2019;7(1):176. [PubMed 31292005].",
    "Hakozaki T, Okuma Y, Omori M, Hosomi Y. Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett. 2019;17(3):2946-2952. [PubMed 30854072].",
    "Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR tirals. Ann Oncol. 2020;31(4):535-53[PubMed 32115349].",
    "Ochi N, Ichihara E, Takigawa N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021;149:73-8[PubMed 33838391].",
    "Cortellini A, Di Maio M, Nigro O, et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021;9(4):e00242[PubMed 33827906].",
    "Takata S, Koh G, Han Y, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. J Infect Chemother. 2019;25(1):54-58. [PubMed 30055859].",
    "Cortellini A, Ricciuti B, Facchinetti F, et al. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021;32(11):1391-1399. [PubMed 34400292].",
    "Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab. Anticancer Res. 2017;37(6):3195-3200. [PubMed 28551664].",
    "Vivotif (typhoid vaccine live oral Ty21a) [prescribing information]. Miami Lakes, FL: Crucell Vaccines Inc.; September 2013.",
    "Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine - advisory committee on immunization practices, United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(11):305-308. [PubMed 25811680].",
    "Wolfe MS. Precautions with oral live typhoid (Ty 21a) vaccine. Lancet. 1990;336(8715):631-632. [PubMed 1975401].",
    "Vaxchora (cholera vaccine) [prescribing information]. Redwood City, CA: PaxVax Inc; June 2016.",
    "Hoffman JT, Hartig C, Sonbol E, Lang M. Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011;45(5):e25. [PubMed 21505109].",
    "Xifaxin (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; October 2022.",
    "Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy. 2005;51(Suppl 1):1-22. [PubMed 15855746].",
    "Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother. 2007;41(2):222-228. [PubMed 17284510].",
    "Xifaxan (rifaximin) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; May 2015.",
    "Aronson JK, Ferner RE. Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives [published online August 18, 2020]. BMJ Evid Based Med. doi: 10.1136/bmjebm-2020-111363. [PubMed 32817012].",
    "Back DJ, Grimmer FM, Orme ML, Proudlove C, Mann RD, Breckenridge AM. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol. 1988;25(5):527-532. [PubMed 3408633].",
    "Sparrow MJ. Pill method failures. N Z Med J. 1987;100(818):102-105. [PubMed 3470667].",
    "Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36(5 pt 1):705-710. [PubMed 9146531].",
    "Murphy AA, Zacur HA, Charache P, Burkman RT. The effect of tetracycline on levels of oral contraceptives. Am J Obst Gynecol. 1991;164(1 pt 1):28-33. [PubMed 1986620].",
    "Neely JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol. 1991;77(3):416-420. [PubMed 1992409].",
    "Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet. 2005;44(4):429-438. [PubMed 15828855].",
    "Maggiolo F, Puricelli G, Dottorini M, Caprioli S, Bianchi W, Suter F. The effect of ciprofloxacin on oral contraceptive steroid treatments. Drugs Exp Clin Res. 1991;17(9):451-454. [PubMed 1822438].",
    "Scholten PC, Droppert RM, Zwinkels MG, Moesker HL, Nauta JJ, Hoepelman IM. No interaction between ciprofloxacin and an oral contraceptive. Antimicrob Agents Chemother. 1998;42(12):3266-3268. [PubMed 9835524].",
    "Pentikis HS, Adetoro N, Braun CJ. Lack of a pharmacokinetic interaction between SYM-1219 granules containing 2 grams of secnidazole and a combined oral contraceptive in a phase 1, randomized, open-label study in healthy female volunteers. Adv Ther. 2017;33(12):2229-224 [PubMed 27744624].",
    "Meyer B, Muller F, Wessels P, Maree J. A model to detect interactions between roxithromycin and oral contraceptives. Clin Pharmacol Ther. 1990;47(6):671-674. [PubMed 2113449].",
    "Grimmer SF, Allen WL, Back DJ, Breckenridge AM, Orme M, Tija J. The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception. 1983;28(1):53-59. [PubMed 6414761].",
    "Back DJ, Breckenridge AM, MacIver M, et al. The effect of ampicillin on oral contraceptive steroids in women. Br J Clin Pharmacol. 1982;14(1):43-48. [PubMed 6809025].",
    "Friedman CI, Huneke AL, Kim MH, Powell J. The effect of ampicillin on oral contraceptive effectiveness. Obstet Gynecol. 1980;55(1):33-37. [PubMed 7188714].",
    "Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46(6):917-923. [PubMed 12063491].",
    "American College of Obstetricians and Gynecologists' Committee on Practice Bulletins - Gynecology; Allen RH, Kaunitz A, Bartz D. ACOG Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133(2):e128-e150. [PubMed 30681544].",
    "Prescribing information. Prepopik (sodium picosulfate, magnesium oxide, and anhydrous citric acid). Parsippany, NJ: Ferring Pharmaceuticals Inc., July 2012.",
    "Modulon (trimebutine) [product monograph]. Mont-Saint-Hilaire, Quebec, Canada: Aptalis Pharma Canada, Inc.; November 2011.",
    "Algiron (cimetropium) tablet [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200900846. Accessed January 12, 2017.",
    "Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125(11):940-941. [PubMed 8967683].",
    "Toohey TP, Lu BY, Wada C. Toxic effects of psychotropics related to possible p450 enzyme inhibition by kava: report of 2 cases. Prim Care Companion CNS Disord. 2013;15(5):PCC.13br01539. [PubMed 24511438].",
    "Perez J, Holmes JF. Altered mental status and ataxia secondary to acute kava ingestion. J Emerg Med. 2005;28(1):49-51. [PubMed 15657005].",
    "Gurley BJ, Swain A, Hubbard MA, et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008;83(1):61-69. [PubMed 17495878].",
    "Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426. [PubMed 15900287].",
    "Sarris J. LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27-35. [PubMed 21073405].",
    "Aricept (donepezil) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2013.",
    "Razadyne (galantamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; June 2013.",
    "Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013.",
    "Bloxiverz (neostigmine methylsulfate) [prescribing information]. Chesterfield, MO: Eclat Pharmaceuticals; May 2013.",
    "Mestinon (pyridostigmine) [prescribing information]. Costa Mesa, CA: ICN Pharmaceuticals Inc; July 2001.",
    "Enlon (edrophonium) [prescribing information]. Lake Forest, IL: Bioniche Pharma USA LLC; March 2010.",
    "Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2011.",
    "Beermann B, Groschinsky-Grind M. Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline. Eur J Clin Pharmacol. 1978;13(5):385-387. [PubMed 668798].",
    "Eid TJ, Horton M, Hendrix C, Yu JM, Browning EA, Malhotra A. A First Report of HCTZ and Dicyclomine Induced Uncharacteristic Contraction Alkalosis. J Pharm Pract. 2023;36(3):679-684. [PubMed 34670427].",
    "Inhibace Plus (cilazapril and hydrochlorothiazide) [product monograph]. Mississauga, ON: Xediton Pharmaceuticals Inc; August 2022.",
    "Hylaton (chlortalidone) [summary of product characteristics]. Leicester, UK: Morningside Healthcare Limited; February 2020.",
    "Diovan HCT (valsartan and hydrochlorothiazide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2020.",
    "Thalitone (chlorthalidone) [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; September 2019.",
    "Microzide (hydrochlorothiazide) [prescribing information]. Madison, NJ: Allergan USA, Inc.; August 2020.",
    "Hyzaar (losartan potassium and hydrochlorothiazide) [prescribing information]. Jersey City, NJ: Organon &amp; Co.; March 2023.",
    "Belsomra (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2020.",
    "BESREMi (ropeginterferon alfa-2b) [prescribing information]. Burlington, MA: PharmaEssentia USA Corporation; November 2021.",
    "Brom (bromperidol) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198800802. Accessed October 27, 2017",
    "Buprenorphine/naloxone sublingual film [prescribing information]. Princeton, NJ: Sandoz Inc.; June 2018.",
    "Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma LP; September 2018.",
    "U.S. Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004. Accessed Online July 8, 2014 at www.ncbi.nlm.nih.gov/books/NBK64245/. [PubMed 22514846].",
    "Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. [PubMed 28315808].",
    "Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. [PubMed 28972983].",
    "Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732-734. [PubMed 30140853].",
    "Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. [PubMed 23423407].",
    "Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885. [PubMed 25299603].",
    "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.",
    "Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martin MA, Altimiras J. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res. 2009;23(12):1795-1796. [PubMed 19441067].",
    "Chen D, Klesmer J, Giovanniello A, Katz J. Mental status changes in an alcohol abuser taking valerian and gingko biloba. Am J Addict. 2002;11(1):75-77. [PubMed 11876586].",
    "Khom S, Baburin I, Timin E, et al. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology. 2007;53(1):178-187. [PubMed 17585957].",
    "Benke D, Barberis A, Kopp S, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. 2009;56(1):174-181. [PubMed 18602406].",
    "Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA. 1998;280(18):1566-1567. [PubMed 9820254].",
    "Gutierrez S, Ang-Lee MK, Walker DJ, Zacny JP. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav. 2004;78(1):57-64. [PubMed 15159134].",
    "Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. 2004;18(10):831-836. [PubMed 15551388].",
    "Hallam KT, Olver JS, McGrath C, Norman TR. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Hum Psychopharmacol. 2003;18(8):619-625. [PubMed 14696021].",
    "Glass JR, Sproule BA, Herrmann N, Streiner D, Busto UE. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23(3):260-268. [PubMed 12826988].",
    "Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426. [PubMed 15900287].",
    "Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(12):1333-1336. [PubMed 15328251].",
    "Cesamet (nabilone) [product monograph]. Quebec, Canada: Valeant Canada Ltd; December 2009.",
    "Benowitz NL,Jones RT. Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades. Clin Pharmacol Ther. 1977;21(3):336-342. [PubMed 837652].",
    "Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60(6):1303-1314. [PubMed 11152013].",
    "Freemon FR, Rosenblatt JE, El-Yousef MK. Interaction of physostigmine and delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther. 1975;17(2):121-6. [PubMed1091392].",
    "Chen HK, Hsieh CJ. Risk of gastrointestinal hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: a retrospective cohort study. Schizophr Res. 2018;195:237-244. [PubMed 29107449].",
    "Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal 'slow gut' reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699-709. [PubMed 28623627].",
    "Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019;33(1):81-91. [PubMed 30456745].",
    "George J, Hotham R, Melton W, Chapple K. Clozapine-induced stercoral colitis: a surgical perspective. BMJ Case Rep. 2019;12(8). pii: e227718. [PubMed 31471354].",
    "Rodrigues A, Duarte A, Marques A, et al. Multiple spontaneous small bowel perforations due to clozapine-case report. Int J Surg Case Rep. 2018;53:262-264. [PubMed 30447547].",
    "Osterman MT, Foley C, Matthias I. Clozapine-induced acute gastrointestinal necrosis: a case report. J Med Case Rep. 2017;11(1):270. [PubMed 28938913].",
    "Pautola L, Hakala T. Medication-induced acute esophageal necrosis: a case report. J Med Case Rep. 2016;10(1):267. [PubMed 27679991].",
    "Osseis M, Lim C, Lahat E, Doussot A, Salloum C, Azoulay D. Hepatic venous outflow block caused by compressive fecaloma in a schizophrenic patient treated with clozapine. Drug Discov Ther. 2015;9(6):422-423. [PubMed 26781928].",
    "Martinez Diaz-Caneja C, Gonzalez-Molinier M, Conejo Galindo J, Moreno Iniguez M. Severe bowel ischemia due to clozapine with complete remission after withdrawal. J Clin Psychopharmacol. 2010;30(4):463-465. [PubMed 20631566].",
    "McKinnon ND, Azad A, Waters BM, Joshi KG. Clozapine-induced bowel infarction: a case report. Psychiatry (Edgmont). 2009;6(3):30-35. [PubMed 19724752].",
    "Leung JS, Lee CC, Lee WK, Kwong PP. Rapidly fatal clozapine-induced intestinal obstruction without prior warning signs. Aust N Z J Psychiatry. 2008;42(12):1073-1074. [PubMed 19031643].",
    "Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatry. 2008;16(3):216-219. [PubMed 18568631].",
    "Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry. 2006;6:43. [PubMed 17052340].",
    "Pelizza L, De Luca P, La Pesa M, Borella D. Clozapine-induced intestinal occlusion: a serious side effect. Acta Biomed. 2007;78(2):144-148. [PubMed 17933283].",
    "Oke V, Schmidt F, Bhattarai B, et al. Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report. Int Med Case Rep J. 2015;8:189-192. [PubMed 26392790].",
    "Yu SC, Chen HK, Lee SM. Rapid development of fatal bowel infarction within 1 week after clozapine treatment: a case report. Gen Hosp Psychiatry. 2013;35(6):679.e5-e6. [PubMed 24199785].",
    "Flanagan RJ, Ball RY. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci Int. 2011;206(1-3):e31-e36. [PubMed 20719440].",
    "Townsend G, Curtis D. Case report: rapidly fatal bowel ischaemia on clozapine treatment. BMC Psychiatry. 2006;6:43. [PubMed 17052340].",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems. Https://www.fda.gov/safety/medical-product-safety-information/clozaril-fazaclo-odt-versacloz-clozapine-drug-safety-communication-fda-strengthens-warning-untreated. Published January 28, 2020. Accessed January 31, 2020.",
    "Clozaril (clozapine) [prescribing information]. Rosemont, PA: HLS Therapeutics USA Inc; March 2020.",
    "Dayvigo (lemborexant) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2019.",
    "Demser (metyrosine) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; July 2021.",
    "Digesan (bromopride) [prescribing information]. Sao Paulo, Brazil: Sanofi-Aventis Farmaceutica Ltda; May 2016.",
    "Dollery CT, Reid JL. Double-blind comparison of the hypotensive, sedative and salivary flow effects of lofexidine and clonidine in normal subjects. Arzneimittelforschung. 1982;32(8a):984-987. [PubMed 6890374].",
    "Lucemyra (lofexidine) [prescribing information]. Louisville, KY: US WorldMeds, LLC; May 2018.",
    "BritLofex (lofexidine) [summary of product characteristics]. Berkshire, UK: Britannia Pharmaceuticals; August 2015.",
    "Dopergin (lisuride) [summary of product characteristics]. North Shore, Auckland, New Zealand: Bayer New Zealand Limited; April 2013.",
    "Droperidol injection [prescribing information]. Shirley, NY: American Regent Inc.; January 2009.",
    "Dry mouth and delayed dissolution of nitroglycerin. N Engl J Med. 1984;310(17):1122-1123. [PubMed 6424013].",
    "Robbins LJ. Dry mouth and delayed dissolution of sublingual nitroglycerin. N Engl J Med. 1983;309(16):985. [PubMed 6413859].",
    "Sato H, Koretsune Y, Taniguchi T, et al. Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial. Arzneimittelforschung. 1997;47(2):128-131. [PubMed 9079231].",
    "Nitrostat (nitroglycerin) sublingual tablets [prescribing information]. New York, NY: Pfizer Inc; May 2011.",
    "Dymista (azelastine/fluticasone) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; September 2018.",
    "Astelin (azelastine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; September 2018.",
    "Astepro (azelastine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; September 2018.",
    "Exelon (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.",
    "Flunarizine [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc.; February 2022.",
    "Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; July 2017.",
    "Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.",
    "GlucaGen (glucagon) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; December 2011.",
    "Green HH, Ray L, Buchanan J, Matsler N. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis. Am J Health Syst Pharm. 2023;80(18):1234-1237. [PubMed 37348110].",
    "Qbrexza (glycopyrronium) [prescribing information]. Scottsdale, AZ: Journey Medical Corporation; October 2022.",
    "Heminevrin (clomethiazole) [UK summary of product characteristics]. Mesekenhagen, Germany: Cheplapharm Arzneimettel GmbH; April 2016.",
    "Igalmi (dexmedetomidine) sublingual film [prescribing information]. New Haven, CT: BioXel Therapeutics, Inc.; April 2022.",
    "Incruse Ellipta (umeclidinium) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2014.",
    "Anoro Ellipta (umeclidinium and vilanterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.",
    "Incruse Ellipta (umeclidinium) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; November 2015.",
    "Irribow (ramosetron) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200905270. Accessed June 17, 2016.",
    "Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: R-Pharm US, LLC; January 2022.",
    "Anon. Higdon J et al: Linus Pauling Institute. Available from: https://tinyurl.com/2p86msf7 [Accessed February 3, 2023].",
    "Worthley LIG. Clinical toxicology: part 1. Diagnosis and management of common drug overdosage. Crit Care Resusc. 2002;4(3):192-215. [PubMed 16573429]",
    "Korsuva (difelikefalin) [prescribing information]. Stamford, CT: Cara Therapeutics, Inc; August 2021.",
    "Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.",
    "Levotuss (levodropropizine) [summary of product characteristics]. Barcelona, Spain: Rottapharm SL; December 2013.",
    "Zyplo (levodropropizine) [summary of product characteristics]. Rio de Janeiro, Brazil: Bago Laboratories of Brazil SA; June 2014.",
    "Levopront (levodropropizine) [summary of product characteristics]. Lugano, Switzerland: Novintethical; January 2014.",
    "Gatti G, Barzaghi N, Dominijanni R, Cordaro C, Perucca E. Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: a placebo-controlled, double-blind comparative study. Drugs Exp Clin Res. 1993;19(1):33-39. [PubMed 8223138].",
    "Lonasen (blonanserin) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200906540. Accessed September 22, 2014.",
    "Matulane (procarbazine) [prescribing information]. Wilmington, NC: Alcami Corporation; August 2018.",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. Clin Pharmacol Ther. 1984;35(6):852-855. [PubMed 6734038].",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet. 1982;2(8307):1059-1061. [PubMed 6127542].",
    "Alsop WR, Moore JG, Rollins DE, Tolman KG. The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate. J Clin Pharmacol. 1984;24(5-6):235-239. [PubMed 6747020].",
    "Cuvposa (glycopyrrolate). Atlanta, GA: Mikart Inc; February 2018.5. Dartisla ODT (glycopyrrolate) orally disintegrating tablets [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC: December 2021.",
    "Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.",
    "Tolvon (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.",
    "Lumin (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.",
    "Clemmesen L, Mikkelsen PL, Lund H, Bolwig TG, Rafaelsen OJ. Assessment of the anticholinergic effects of antidepressants in a single-dose cross-over study of salivation and plasma levels. Psychopharmacology (Berl). 1984;82(4):348-354. [PubMed 6427827].",
    "Kopera H. Anticholinergic and blood pressure effects of mianserin, amitriptyline and placebo. Br J Clin Pharmacol. 1978;5 Suppl 1:29S-34S. [PubMed 341941].",
    "Mirapex (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2021.",
    "Myrbetriq (mirabegron extended-release) [prescribing information]. Northbrook, IL: Astellas Pharm US Inc; June 2012.",
    "Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008;77(5):643-650. [PubMed 18350762]",
    "Neupro (rotigotine) [prescribing information]. Smyrna, GA: UCB Inc; July 2021.",
    "Norgesic (orphenadrine and paracetamol) [summary of product characteristics]. Chatswood, New South Wales, Australia: iNova Pharmaceuticals (Australia) Pty Limited; January 2014.",
    "Nozinan (methotrimeprazine) [product monograph]. Laval, Quebec, Canada: sanofi-aventis Canada Inc.; February 2020.",
    "Panectyl (trimeprazine) [product monograph]. Montreal, Quebec, Canada: ERFA Canada 2012 Inc; December 2015.",
    "Paraldehyde injection BP [product monograph]. Montreal, QC: Omega Laboratories Ltd; February 2011.",
    "Patanase (olopatadine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2021.",
    "Ryaltris (olopatadine and mometasone) [prescribing information]. Columbus, OH: Hikma Specialty USA Inc.; January 2022.",
    "Paxil (paroxetine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2011.",
    "Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; April 2011.",
    "Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer Inc; April 2011.",
    "Celexa (citalopram) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc; January 2019.",
    "Lexapro (escitalopram) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc; January 2019.",
    "Luvox CR (fluvoxamine) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc; January 2017.",
    "Viibryd (vilazodone) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc; January 2020.",
    "Prescribing information. Atrovent HFA (ipratropium). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., October 2011.",
    "Prescribing information. Diclegis (doxylamine/pyridoxine). Bryn Mawr, PA: Duchesnay USA, Inc., 4/2013.",
    "Prescribing information. Intermezzo (zolpidem). Point Richmond, CA: Transcept Pharmaceuticals, Inc., November 2011.",
    "Prescribing information. Edluar (zolpidem). Somerset, NJ: Meda Pharmaceuticals Inc., 10/10.3. Prescribing information. Ambien (zolpidem). Bridgewater, NJ: sanofi-aventis U.S. LLC, August 2010.",
    "Prescribing information. Mirvaso (brimonidine). Fort Worth, TX: Galderma Laboratories, L.P., August 2013.",
    "Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” J AAPOS, 2003, 7(1):69-70. [PubMed 12690374].",
    "Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” Pediatr Emerg Care, 2008, 24(3):167-9. [PubMed 18347496].",
    "Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” J Pediatr, 2001, 138(3):441-3. [PubMed 11241061].",
    "Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” J AAPOS, 2001, 5(5):281-4. [PubMed 11641636].",
    "Prescribing information. MS Contin (morphine). Stamford, CT: Purdue Pharma L.P., July 2012.",
    "Prescribing information. Oxycontin (oxycodone). Stamford, CT: Purdue Pharma L.P., 04/2013.",
    "Prescribing information. Zohydro ER (hydrocodone). San Diego, CA: Zogenix, Inc., 10/2013.",
    "Prescribing information. Exalgo (hydromorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2013.",
    "Clark K, Lam LT, Agar M, Chye R, Currow DC. The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. Palliat Med. 2010;24(4):410-8. [PubMed 20348271].",
    "Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-88. [PubMed 18422378].",
    "Prescribing information. Spiriva (tiotropium). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., March 2012.",
    "Prescribing information. Thalidomid (thalidomide). Summit, NJ: Celgene Corporation, February 2013.",
    "Quviviq (daridorexant) [prescribing information]. Radnor, PA: Idorsia Pharmaceuticals US Inc; January 2022.",
    "Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.",
    "Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011.",
    "Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015.",
    "Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015.",
    "Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.",
    "Reglan (metoclopramide) [prescribing information]. Baudette, MN: Ani Pharmaceuticals Inc; August 2017.",
    "Requip XL (ropinirole) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2021.",
    "Rinlaxer (chlorphenesin carbamate) [prescribing information]. Toshima, Tokyo, Japan: Taisho Pharmaceutical Co., Ltd.; July 2009.",
    "Rohypnol [prescribing information]. Rio de Janeiro RJ, Brasil: Roche Chemicals and Pharmaceuticals SA; May 2014.",
    "Hypnodorm [product information]. New South Wales, Australia: Alphapharm Pty Limited; May 2007.",
    "Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-513. [PubMed 18332297].",
    "Seebri Neohaler (glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.",
    "Seebri Breezhaler (glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; July 2015.",
    "Utibron Neohaler (indacaterol and glycopyrrolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.",
    "Ultibro Breezhaler (indacaterol and glycopyrronium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc.; August 2014.",
    "Siguent Hycor (hydrocortisone) ophthalmic ointment [summary of product characteristics]. St Leonards, New South Wales, Australia: Aspen Pharma Pty Ltd; August 2013.",
    "Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490].",
    "Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581].",
    "Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976].",
    "McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345].",
    "Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282].",
    "Magnesium sulfate [prescribing information]. Schaumburg, IL: APP Pharmaceuticals LLC; January 2008.",
    "Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira Inc; November 2009.",
    "Minocin (minocycline) injection [prescribing information]. Parsippany, NJ: The Medicines Company; April 2015.",
    "Sikendar RI, us Samad B, Ali S, Memon MI. Post traumatic tetanus and role of magnesium sulphate. J Ayub Med Coll Abbottabad. 2009;21(2):132-135. [PubMed 20524490].",
    "Khafagy HF, Osman ES, Naguib AF. Effects of different dose regimens of magnesium on pharmacodynamics and anesthetic requirements of balanced general anesthesia. J Egypt Soc Parasitol. 2007;37(2):469-482. [PubMed 17985581].",
    "Bilir A, Gulec S, Erkan A, Ozcelik A. Epidural magnesium reduces postoperative analgesic requirement. Br J Anaesth. 2007;98(4):519-523. [PubMed 17324976].",
    "Walia C, Gupta R, Kaur M, Mahajan L, Kaur G, Kaur B. Propofol sparing effect of dexmedetomidine and magnesium sulfate during BIS targeted anesthesia: A prospective, randomized, placebo controlled trial. J Anaesthesiol Clin Pharmacol. 2018;34(3):335-340. [PubMed 30386016].",
    "Yoldas H, Yildiz I, Karagoz I, et al. Effects of bispectral index-controlled use of magnesium on propofol consumption and sedation level in patients undergoing colonoscopy. Medeni Med J. 2019;34(4):380-386. [PubMed 32821465].",
    "Chen J, Qian K, Liu CH., Li XL, Chen Y, Wang JQ. Effects of intravenous administration of magnesium sulfate in propofol-based sedation for ERCP in elderly patients: a randomized, double-blind, placebo-controlled study. BMC Geriatr. 2023;23(1):413. [PubMed 37420201].",
    "McDonnell NJ, Muchatuta NA, Paech MJ. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery. Int J Obstet Anesth. 2010;19(2):226-231. [PubMed 20219345].",
    "Robins K, Lyons G. Opioid-related narcosis in a woman with myopathy receiving magnesium. Int J Obstet Anesth. 2007;16(4):367-369. [PubMed 17643282].",
    "Magnesium sulfate [prescribing information] injection. Lake Zurich, IL: Fresenius Kabi; September 2021.",
    "Magnesium sulfate [prescribing information]. Lake Forest, IL: Hospira, Inc; July 2022.",
    "Spravato (esketamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2019.",
    "Superan (alizapride) [summary of product characteristics]. Sao Paulo, Brazil: Sanofi-Aventis Pharmaceuticals Ltda; August 2016.",
    "Symlin (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2015.",
    "Symmetrel (amantadine) tablets [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals Inc; January 2009.",
    "Gocovri (amantadine) extended-release capsules [prescribing information]. Emeryville, CA: Adamas Pharma LLC; August 2017.",
    "Tarnin (chlorprothixene) [Taiwanese product labeling]. Nantou City, Taiwan: Shou Chan Industrial Co., Ltd.; June 2023.",
    "Tinset (oxatomide) tablet [KR Prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199303099. Accessed November 24, 2014.",
    "Topamax (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2011.",
    "Qsymia (phentermine/topiramate) [prescribing information]. Mountain View, CA: Vivus Inc; July 2012.",
    "Toplexil (oxomemazine) syrup [Qatar patient leaflet]. Saint Genis Laval, France: Sanofi-Aventis France; September 2010.",
    "Trivastal (piribedil) [summary of product characteristics]. Les Laboratories Servier; August 2013.",
    "Tudorza Pressair (aclidinium) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2019.",
    "Duaklir Pressair (aclidinium bromide and formoterol fumarate) [prescribing information]. Morrisville, NC: Circassia Pharmaceuticals Inc.; March 2019.",
    "Urocit-K (potassium citrate) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; December 2009.",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. Clin Pharmacol Ther. 1984;35(6):852-855. [PubMed 6734038].",
    "McMahon FG, Ryan JR, Akdamar K, Ertan A. Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet. 1982;2(8307):1059-1061. [PubMed 6127542].",
    "Alsop WR, Moore JG, Rollins DE, Tolman KG. The effects of five potassium chloride preparations on the upper gastrointestinal mucosa in healthy subjects receiving glycopyrrolate. J Clin Pharmacol. 1984;24(5-6):235-239. [PubMed 6747020].",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Published December 19, 2019. Accessed December 19, 2019.",
    "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.",
    "Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98. [PubMed 26333030].",
    "Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698. [PubMed 26063215].",
    "Muzzaale AD, Daubresse M, Bae S, Chu NM, Lentine KL, Segev DL, McAdams-DeMarco M. Benzodiazepines, codispensed opioids, and mortality among patients initiating long-term in-center hemodialysis. Clin J Am Soc Nephrol. 2020;15(6):794-804. [PubMed 32457228].",
    "Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. [PubMed 28315808].",
    "Silbert BS, Rosow CE, Keegan CR, et al. The effect of diazepam on induction of anesthesia with alfentanil. Anesth Analg. 1986;65(1):71-77. [PubMed 3079632].",
    "Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. [PubMed 28972983].",
    "Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732-734. [PubMed 30140853].",
    "Li Y, Delcher C, Wei Y-JJ, Reisfield GM, Brown JD, Tighe P, Winterstein AG. Risk of opioid overdose associated with concomitant use of opioid and skeletal muscle relaxants: a population-based cohort study. Clin Pharmacol Ther. 2020;108(1):81-89. [PubMed 32022906].",
    "Yang RM, Oh IS, Li J, Jeon HL, Shin JY. Association between opioid analgesic plus benzodiazepine use and death: a case-crossover study. J Psychosom Res. 2020;135:110153. [PubMed 32504894].",
    "Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. [PubMed 23423407].",
    "Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885. [PubMed 25299603].",
    "Moran KM, Calip GS, Lee TA, Koronkowski MJ, Lau DT, Schumock GT. Risk of fall-related injury and all-cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: a case-time-control analysis. [published online ahead of print] Pharmacotherapy. 2021. doi: 10.1002/phar.2612. [PubMed 34328644].",
    "US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.",
    "FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.",
    "Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17(1):85-98. [PubMed 26333030].",
    "Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study [published online June 10, 2015]. BMJ. doi: 10.1136/bmj.h2698. [PubMed 26063215].",
    "Abrahamsson, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. [PubMed 28315808].",
    "Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med. 2017;14(10):e1002396. [PubMed 28972983].",
    "Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732-734. [PubMed 30140853].",
    "Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657-659. [PubMed 23423407].",
    "Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. MMWR Morb Mortal Wkly Rep. 2014;63(40):881-885. [PubMed 25299603].",
    "Roxicodone (oxycodone) [prescribing information]. Newport, KY: Xanodyne Pharmaceuticals Inc; March 2009.",
    "Targiniq ER (oxycodone/naloxone) extended-release tablets [prescribing information]. Stamford CT: Purdue Pharma LP; July 2014.",
    "Oxycontin (oxycodone) extended-release tablets [prescribing information]. Stamford CT: Purdue Pharma LP; August 2015.",
    "US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D. on FDA advisory about deadly risks associated with kratom. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-fda-advisory-about-deadly-risks-associated-kratom. Accessed September 15, 2021.",
    "US Food and Drug Administration. FDA and kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom. Accessed September 15, 2021.",
    "Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol. 2011;35(4):242-247. [PubMed 21513619].",
    "Wang C, Walker AE. Fatal mitragynine-associated toxicity in Canada: a case report and review of the literature. Acad Forensic Pathol. 2018;8(2):340-346.[PubMed 31240047].",
    "Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J Jr, Solomon CJ, Levine B. A drug toxicity death involving propylhexedrine and mitragynine. J Anal Toxicol. 2011;35(1):54-59. [PubMed 21219704].",
    "Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol. 2010;6(4):424-426. [PubMed 20411370].",
    "Gershman K, Timm K, Frank M, et al. Deaths in Colorado attributed to Kratom. N Engl J Med. 2019;380(1):97-98. [PubMed 30601742].",
    "Tatum WO, Hasan TF, Coonan EE, Smelick CP. Recurrent seizures from chronic kratom use, an atypical herbal opioid. Epilepsy Behav Case Rep. 2018;10:18-20. [PubMed 30062086].",
    "Mitchell-Mata C, Thomas B, Peterson B, Couper F. Two fatal intoxications involving 3-Methoxyphencyclidine. J Anal Toxicol. 2017;41(6):503-507. [PubMed 28830118].",
    "Domingo O, Roider G, Stover A, et al. Mitragynine concentrations in two fatalities. Forensic Sci Int. 2017;271:e1-e7. [PubMed 28089300].",
    "Neerman MF, Frost RE, Deking J. A drug fatality involving Kratom. J Forensic Sci. 2013;58(Suppl 1):S278-S279. [PubMed 23082895].",
    "Singh D, Narayanan S, Grundmann O, Boyer EW, Vicknasingam B. The use of benzodiazepines among Kratom (Mitragyna Speciosa Korth.) users. J Psychoactive Drugs. 2020;52(1):86-92.[PubMed 31218929].",
    "Karinen R, Fosen JT, Rogde S, Vindenes V. An accidental poisoning with mitragynine. Forensic Sci Int. 2014;245:e29-e32. [PubMed 25453780].",
    "Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016;130(1):127-138.[PubMed 26511390].",
    "Valenzuela JE, Weiner K, Saad C. Cholinergic stimulation of human pancreatic secretion. Dig Dis Sci. 1986;31(6):615-619. [PubMed 2872022].",
    "Kuvshinoff BW, Demar AR, James L, McFadden DW, Fink AS. Effect of pancreatic denervation and atropine on the pancreatic response to secretin. Pancreas. 1993;8(5):609-614. [PubMed 8302798].",
    "Park HS, Lee YL, Kwon HY, Chey WY, Park HJ. Significant cholinergic role in secretin-stimulated exocrine secretion in isolated rat pancreas. Am J Physiol. 1998;274(2 pt 1):G413-G418. [PubMed 9486197].",
    "Chey WY, Chang TM. Neural control of the release and action of secretin. J Physiol Pharmacol. 2003;54(suppl 4):105-112. [PubMed 15075453].",
    "Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.",
    "Viberzi (eluxadoline) [prescribing information]. Cincinnati, OH: Patheon Pharmaceuticals Inc; May 2015.",
    "Vibrocil nasal drops, nasal gel, nasal spray, and microdoser (dimetindene maleate/phenylephrine base) [prescribing information]. Petach-Tikva, Israel: Promedico Ltd; November 1998.",
    "Vistaril (hydroxyzine) [prescribing information]. New York, NY: Pfizer Inc; September 2019.",
    "Welldorm (cloral betaine) [summary of product characteristics]. Marlborough, Wiltshire, United Kingdom: Marlborough Pharmaceuticals Ltd; December 2014.",
    "Worthley LI. Clinical toxicology: Part I. Diagnosis and management of common drug overdosage. Crit Care Resusc. 2002;4(3):192-215. [PubMed 16573429]",
    "Xywav (calcium, magnesium, potassium, and sodium oxybates) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; July 2020.",
    "Xyrem (sodium oxybate) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; July 2020.",
    "Yupelri (revefenacin) [prescribing information]. Morgantown, WV: Mylan Specialty LP; November 2018.",
    "Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc.; March 2019.",
    "Zurzuvae (zuranolone) [prescribing information]. Cambridge, MA: Biogen Inc; August 2023.",
    "GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Novel Laboratories, Inc.; March 2022.",
    "GoLYTELY (polyehtylene glycol 3350 and electrolytes) [prescribing information]. May 2021.",
    "Moviprep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2022.",
    "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; May 2021.",
    "Colyte with Flavor Packs (peg-3350 and electrolytes) [prescribing information]. Somerset, NJ: MEDA; May 2021.",
    "GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Novel Laboratories, Inc.; March 2022.",
    "GoLYTELY (polyehtylene glycol 3350 and electrolytes) [prescribing information]. May 2021.",
    "Moviprep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2022.",
    "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; May 2021.",
    "Colyte with Flavor Packs (peg-3350 and electrolytes) [prescribing information]. Somerset, NJ: MEDA; May 2021.",
    "Bi-Peglyte (polyethylene glycol 3350 and electrolytes and bisacodyl delayed release) [prescribing information]. Montreal, Quebec, Canada: Pharmascience Inc.; October, 2015.",
    "Suflave (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride) [prescribing information]. Holbrook, MA: Braintree Laboratories, Inc.; June 2023.",
    "GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Novel Laboratories, Inc.; March 2022.",
    "GoLYTELY (polyehtylene glycol 3350 and electrolytes) [prescribing information]. May 2021.",
    "Moviprep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2022.",
    "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; May 2021.",
    "Suflave (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride) [prescribing information]. Holbrook, MA: Braintree Laboratories, Inc.; June 2023.",
    "Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.",
    "Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909].",
    "Suflave (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride) [prescribing information]. Holbrook, MA: Braintree Laboratories, Inc.; June 2023.",
    "GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Novel Laboratories, Inc.; March 2022.",
    "GoLYTELY (polyethylene glycol 3350 and electrolytes) [prescribing information]. May 2021.",
    "Moviprep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2022.",
    "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; May 2021.",
    "Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. Arch Dis Child. 2011;96(9):888-889. [PubMed 21785118].",
    "Detinox Infant Colic Drops (dimethicone) [summary of product characteristics]. Watford, Hertfordshire, UK: DDD Limited; August 2012.",
    "Huupponen R, Seppala P, Iisalo E. Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol. 1984;26:279-281. [PubMed 6327318].",
    "Reissell P, Manninen V. Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides. Acta Med Scand Suppl. 1982;668:88-90. [PubMed 6963097].",
    "Johnson BF, Rodin SM, Hoch K, et al. The effect of dietary fiber on the bioavailability of digoxin in capsules. J Clin Pharmacol. 1987;27:487-490. [PubMed 2821081].",
    "Nordstrom M, Melander A, Robertsson E, et al. Influence of wheat bran and of a bulk-forming ispaghula cathartic on the bioavailability of digoxin in geriatric in-patients. Drug Nutr Interact. 1987;5:67-69. [PubMed 3038494].",
    "Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation. 1978;58:164-172. [PubMed 647881].",
    "Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015.",
    "Mann NS, Borkar BB, Narenderan KP, Kadian RS, Mann SK, Martin RL. Effect of lactulose, neomycin and antacid on colonic pH recorded continuously with an implanted electrode. Am J Gastroenterol. 1979;72(2):141-145. [PubMed 38663].",
    "Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029].",
    "Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.",
    "Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909].",
    "Speedon powder (lactitol) [prescribing information]. Taiwan: Nam Kwong Chemical Pharmaceutical Co Ltd; October 2015.",
    "Patil DH, Wetaby D, Mahida YR, et al. Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut. 1987;28(3):255-259. [PubMed 3570029].",
    "Pirotte J, Guffens JM, Devos J. Comparative study of basal arterial ammonemia and of orally-induced hyperammonemia in chronic portal systemic encephalopathy, treated with neomycin, lactulose, and an association of neomycin and lactulose. Digestion. 1974;10(6):435-444. [PubMed 4448315].",
    "Weber FL Jr, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology. 1982;82(2):213-217. [PubMed 7054022].",
    "Weber FL Jr, Banwell JG, Fresard KM, Cummings JH. Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: effects of lactulose and lactulose plus neomycin. J Lab Clin Med. 1987;110(3):259-263. [PubMed 3611949].",
    "Capocaccia L, Riggio O. Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: do they enhance each other? Hepatology. 1990;12(2):368-370. [PubMed 2391075].",
    "Martin AJ. Portal systemic encephalopathy--should lactulose and neomycin be used together. Br J Clin Pract. 1981;35(9):323-324. [PubMed 7326185].",
    "Keveyis (dichlorphenamide) [prescribing information]. Trevose, PA: Strongbridge US Inc.; November 2019.",
    "Cohen F. Open-label, dose-escalation, phase 1 study of safety and single and multiple-dose pharmacokinetics of dichlorphenamide in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(1):87-94. [PubMed 29762909].",
    "GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Novel Laboratories, Inc.; March 2022.",
    "GoLYTELY (polyehtylene glycol 3350 and electrolytes) [prescribing information]. May 2021.",
    "Moviprep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2022.",
    "Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; May 2021.",
    "Colyte with Flavor Packs (peg-3350 and electrolytes) [prescribing information]. Somerset, NJ: MEDA; May 2021.",
    "Bi-Peglyte (polyethylene glycol 3350 and electrolytes and bisacodyl delayed release) [prescribing information]. Montreal, Quebec, Canada: Pharmascience Inc.; October, 2015.",
    "Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) [prescribing information]. Holbrook, MA: Braintree Laboratories; November 2020.",
    "Suprep Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate) [prescribing information]. Braintree, MA: Braintree Laboratories, Inc.; July 2020.",
    "Suclear (sodium sulfate, potassium sulfate, and magnesium sulfate; and PEG-3350, sodium chloride, sodium bicarbonate, and potassium chloride) [prescribing information]. Braintree, MA: Braintree Laboratories Inc; January 2013.",
    "Ganaton (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.",
    "Monurol (fosfomycin) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2018.",
    "Levopride (levosulpiride) [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=199501757. Accessed September 1, 2014.",
    "Provenzani A, D'alessandro N, Polidori P. Toxic tacrolimus concentrations associated with intravenous use of metoclopramide in a lung transplant patient. Ann Pharmacother. 2019;53(5):548-549. [PubMed 30739475]",
    "Prescott WA Jr, Callahan PL, Park JM. Tacrolimus toxicity associated with concomitant metoclopramide therapy. Pharmacotherapy 2004;24(4):532-537. [PubMed 15098810]",
    "Wadhw NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc. 1987;19(1 pt 2):1730-1733. [PubMed 3547879]",
    "Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; August 2019.",
    "Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” Br Med J, 1973, 1:587. [PubMed 4694406]",
    "Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” Br J Clin Pharmacol, 1981, 11:430-1P.",
    "Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” J Pharm Pharmacol, 2001, 53(7):1041-5. [PubMed 11480539]",
    "van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” Methods Find Exp Clin Pharmacol, 1990, 12(4):291-4. [PubMed 2374477]",
    "van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” Methods Find Exp Clin Pharmacol, 1992, 14(5):379-82. [PubMed 1513194]",
    "Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” Br J Clin Pharmacol, 1983, 15(4):487-9. [PubMed 6849786]",
    "Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” Cephalalgia, 1988, 8(3):139-47. [PubMed 31970094]",
    "Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” Eur J Clin Pharmacol, 1992, 42(2):235-6. [PubMed 1618258]",
    "Resotran (prucalopride) [product monograph]. Toronto, Ontario, Canada: Janssen Inc.; April 2018.",
    "Motegrity (prucalopride) [prescribing information]. Lexington, MA: Shire US Inc.; December 2018.",
    "Resotran (prucalopride) [product monograph]. Toronto, Ontario, Canada: Janssen Inc.; April 2018.",
    "Motegrity (prucalopride) [prescribing information]. Lexington, MA: Shire US Inc.; December 2018.",
    "Reglan (metoclopramide) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; August 2011.",
    "Reglan ODT (metoclopramide) [prescribing information]. Marietta, GA: Alaven Pharmaceutical LLC; November 2011.",
    "Gasmotin (mosapride) tablets [KR prescribing information]. Available at: https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200100565. Accessed May 1, 2015.",
    "Ditropan XL (oxybutynin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2015.",
    "Bentyl (dicyclomine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US Inc; January 2013.",
    "Resotran (prucalopride) [product monograph]. Toronto, Ontario, Canada: Janssen Inc.; April 2018.",
    "Motegrity (prucalopride) [prescribing information]. Lexington, MA: Shire US Inc; December 2018."
]